WO2010149172A2

WO2010149172A2 - SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.

Info

Publication number: WO2010149172A2
Application number: PCT/DK2010/050163
Authority: WO
Inventors: Pär JOHANSSON
Original assignee: Rigshospitalet
Priority date: 2009-06-24
Filing date: 2010-06-24
Publication date: 2010-12-29
Also published as: WO2010149172A3

Abstract

The present invention relates to a novel use and methods of treatment using the combination of clotting factors and sympathicomimetic / adrenergic receptor agonists with pro-hemostatic activity. Administration of a combination of clotting factors and sympathicomimetic / adrenergic receptor agonists increases blood clot strength as visualized by TEG analyses. The compounds of the invention are particularly useful in the treatment of trauma patients.

Description

Systemic pro-hemostatic effect of clotting factors in combination with sympathicomimetics with agonistic effects on α-adrenergic and/or β-adrenergic receptors of the sympathetic nervous system, related to improved clot strength.

All patent and non-patent references cited in the application, or in the present application, are also hereby incorporated by reference in their entirety.

Field of invention

The present invention relates to a novel use and methods of treatment using the combination of clotting factors and sympathicomimetic / adrenergic receptor agonists with pro-hemostatic activity.

Background of invention

Blood coagulation is a process consisting of a complex interaction of various blood components (or factors) that eventually gives rise to a fibrin clot [Roberts et al. 2006]. Generally, the blood components, which participate in what has been referred to as the coagulation "cascade", are enzymatically inactive proteins (proenzymes or zymogens) that are converted to proteolytic enzymes by the action of an activator (which itself is an activated clotting factor). Coagulation factors that have undergone such a conversion are generally referred to as "active factors", and are designated by the addition of the letter "a" to the name of the coagulation factor (e.g. Factor Vila). Initiation of the hemostatic process is mediated by the formation of a complex between tissue factor, exposed as a result of injury to the vessel wall, and Factor Vila [Roberts et al. 2006]. This complex then converts Factors IX and X to their active forms. Factor Xa converts limited amounts of prothrombin to thrombin on the tissue factor-bearing cell. Thrombin activates platelets and Factors V and VIII into Factors Va and Villa, both cofactors in the further process leading to the full thrombin burst. This process includes generation of Factor Xa by Factor IXa (in complex with factor Villa) and occurs on the surface of activated platelets. Thrombin finally converts fibrinogen to fibrin resulting in formation of a fibrin clot. In recent years Factor VII and tissue factor have been found to be the main initiators of blood coagulation.

It is often desirable to stimulate or improve the coagulation competence in a subject to control bleeding disorders that have several causes such as clotting factor deficiencies (e.g. hemophilia A and B or deficiency of coagulation Factors Xl or VII) or clotting factor inhibitors [Singh et al. 2007] and also to control excessive bleeding occurring in subjects with a normally functioning blood clotting cascade (no clotting factor deficiencies or inhibitors against any of the coagulation factors). Such bleeding may, for example, be caused by a defective platelet function, thrombocytopenia or von Willebrand's disease [Brace 2007]. Bleeding is also a major problem in connection with surgery and other forms of tissue damage [Vaslev et al. 2002, Hardy et al. 2005].

In order to control the bleeding for example in connection with surgery or trauma a multifaceted treatment of the bleeding is initiated, including the below examples of treatments which are performed either alone or in combination:

1. Surgical hemostatic techniques by diathermia, clamping, sutures or packaging,

2. Administration of blood products such as red blood cells (RBC), plasma, containing coagulation factors and platelets,

3. Endovascular treatment (coiling), 4. Local hemostatic compounds including fibrin glue, pads with thrombin and other coagulation factors, local injection of vasoconstrictors, 5. Pro-hemostatic pharmaceuticals such as recombinant factor Vila, recombinant factor XIIIa, and factor concentrates either produced from human plasma or by recombinant technique for FVIII and FIX, 6. Antifibrinolytic pharmaceuticals such as aprotinin, tranexamic acid and others

[Cheung et al. 2007].

Pivotal for many of these medical treatments and procedures are the administration of allogenic blood products [Ferraris et al. 2007]. However, administration of allogenic blood products is associated with development of transfusion related complications such as: a) intravascular hemolytic transfusion reaction, b) delayed hemolytic transfusion reaction, c) transfusion related acute lung injury (TRALI), d) transfusion transmitted infections by virus (HTLV, HIV 1 , 2, Hepatitis B, C,

CMV) or bacteria, e) transfusion associated graft versus host reaction (TA-GVHD), f) posttransfusions purpura (PTP) [Stainsby et al. 2006]. In addition, transfusion of allogenic blood products is also associated with immunomodulation and immunosuppression predisposing for the development of postoperative infections as reported in orthopedic, burn and colorectal surgery [Banbury et al. 2006, Jeschke et al. 2007, Milasiene et al. 2007]. Furthermore, it has been reported by several groups that administration of blood products is independently associated with an increase in development of multiorgan failure [Zallen et al 1999] and mortality [Herbert et al. 1999, Engoren et al. 2002, Karkouti et al. 2004]. In fact, administration of red blood cells to patients undergoing surgical revascularization of coronary arteries dose-dependently is associated with increased 5 year mortality [Engoren et al. 2002]. In addition, transfusion of blood products may result in microchimerism with the immunocompetent donor leukocytes surviving indefinitely in the recipient [Reed et al. 2007].

Accordingly, in treatment of bleeding episodes, e.g. due to trauma, surgery or other medical treatments, the above-mentioned hazards of allogenic blood transfusion and the increasing shortage of allogenic blood donors and hence shortage of blood products calls for new options for pro-hemostatic treatments that improve the subjects clotting ability and hence reduce the bleeding and the need for allogenic blood transfusion in these subjects, without compromising the safety of the recipient.

rFVIIa is a genetically engineered protein expressed from cloned human FVII genes in baby hamster kidney cells. No material of human origin is used in either the production process or in the final product. Thus rFVIIa is less likely than human blood products to transmit infectious agents. rFVIIa is currently approved worldwide for the treatment of bleeding in patients with haemophilia A or B with inhibitors to coagulation factors VIII or IX [Hoffman, 2003]. In Europe, the use of rFVIIa is also approved for factor VII deficiency and Glanzmann's thrombasthenia in patients who are refractory to platelet transfusions, but it is not approved as an adjunctive treatment for massive or coagulopathic bleeding in any country. In cases of injury, tissue factor (TF) is brought into contact with naturally occurring FVIIa present in minute quantities to initiate the coagulation pathway [Gabriel et al., 2004]. At a pharmacological dose, rFVIIa binds to activated platelets at the site of injury and activate factors IX and X, leading to a thrombin burst [Toschi et al., 1997]. As platelets are activated only at sites of TF exposure, it is believed that the action of rFVIIa is localised to these sites. Nevertheless, a primary concern of treatment with rFVIIa is the possibility of an increased incidence of thrombotic adverse events from systemic activation of the coagulation pathway or from TF exposure at sites not associated with tissue injury. Thus, advanced atherosclerotic disease, crush injury, septicaemia and disseminated intravascular coagulation may have an increased risk of developing thrombotic events in association with rFVIIa treatment [Martinowitz et al., 2002]. Use of rFVIIa for off-label exists based upon case reports and small case series and anecdotal experience [Dutton and Stein, 2006; Levy et al., 2006; Kenet et al., 1999; Clark et al., 2004] demonstrating benefit for reducing bleeding in critically ill patients, and that is so although the use of rFVIIa in intractable bleeding is questioned [Johansson 2008]. Routine administration of rFVIIa in non-haemophilic patients to limit or to prevent bleeding and transfusion requirements is not supported by evidence from the reported 17 randomized clinical trials to date [Friederich et al., 2003].

In order to reduce blood loss locally, vasoconstrictors such as adrenaline and noradrenaline have also been used as a treatment alternative. By local administration of vasoconstrictors the peripheral blood vessels are constricted whereby blood loss is reduced. By employing local administration, the systemic effects normally associated with vasoconstrictors are avoided, such as, for example, elevated systemic blood pressure and thus increased blood loss through open vessels.

Several reports exist on the use of vasoconstrictors as local hemostatic agents. For example in US 2007/0073210 is disclosed a wound dressing comprising a vasoconstrictive medicinal substance, such as adrenaline, as a ready to use product for local treatment of bleeding wounds.

Local administration of vasoconstrictors, such as adrenaline and noradrenaline, to a hemodialysis site in order to reduce complications associated with hemodialysis therapy is disclosed in US20050075597.

In WO0182937 compositions of intermacromolecular complexes such as, e.g. polyether, polyacids and polyalkylene and methods for making and using such compositions in reducing post-surgical bleeding is described. The application further describes the incorporation of vasoconstrictors in these compositions in order to have a local drug delivery at a surgical site. Furthermore, the use of vasoconstrictors in a method to control gastrointestinal bleeding when injected directly into the peritoneal cavity or intragastrically is described US 4,337,573. By this method, a local effect is obtained without any unwanted systemic effects because the vasoconstrictors are absorbed into the portal system and inactivated before entering systemic circulation.

In all these cited reports use is made of the vasoconstrictor effects of e.g. adrenaline and noradrenaline on the peripheral blood vessels by local administration in order to reduce bleeding.

In WO 2009/043355 it was shown that administration of a very low dose of sympathicomimetic agonists activated the hemostatic system without causing any significant elevation of the blood pressure.

Summary of invention

The inventor of the present invention has surprisingly found that systemic administration of the combination of clotting factors such as prothrombin complex concentrate factors or single coagulation factors such as factor FVIIa and sympathicomimetic agonists such as adrenaline and noradrenaline in low doses (10 to a 100 times lower than in the current indications i.e. cardiac arrest, anaphylactic shock), will result in a systemic activation of the coagulation system, while at the same time avoiding the side effects such as elevated blood pressure, and thus increased blood loss through open vessels, that would counteract the benefits of the treatment. By administration of clotting factors in combination with low doses of systemic sympathicomimetic agonists, a faster and stronger thrombin generation will take place, which will result in faster clot formation, and a stronger and more durable clot, which is more resistant to shear forces and fibrinolytic enzymes. As a consequence of this, the systemic treatment with clotting factors such as prothrombin complex concentrate factors together with sympathicomimetic agonists such as adrenaline, noradrenaline, dopamine, dobutamine and ephedrine etc. in low doses are contemplated to reduce bleeding and/or risk of bleeding.

As will be described in further detail in the below, the inventor envisages that any clotting factor including prothrombin complex concentrate factors and any sympathicomimetic substance, including adrenaline and noradrenaline, can be used in the present invention.

Thus, one object of the present invention relates to the effect of a combination of clotting factors and sympathicomimetic agonists, resulting in a faster maximal haemostatic effect, when administered systemically by way of intravenous, intramuscular or subcutaneous, intrapulmonary, intra-alveolarly, oral, sublingual, mucosal, or rectal routes as well as any nucleic acid constructs encoding such clotting factors and agonists, vectors and host cells comprising and expressing the nucleic acids, pharmaceutical compositions, uses and methods of treatment.

The present invention relates to novel uses and methods of treatment using the combination of clotting factors and sympathicomimetic agonists with pro-hemostatic activity resulting in a faster maximal haemostatic effect, improved clot strength, as well as nucleic acid constructs encoding such clotting factors and sympathicomimetic agonists, vectors and host cells comprising and expressing the nucleic acids and pharmaceutical compositions.

Thus an object of the present invention relates to the combination of a clotting factor and an adrenergic receptor agonist for systemic administration for the treatment and/or prophylaxis of bleeding in a subject.

Another object of the present invention relates to novel uses and methods of treatment using a combination of clotting factors and sympathicomimetic agonists with pro- hemostatic activity in combination with compounds capable of blocking or minimizing any adverse effects that may be elicited by administration of the sympathicomimetic agonists.

A third object of the present invention relates to novel uses and methods of treatment using the combination of clotting factors and sympathicomimetic agonists with pro- hemostatic activity in combination with potassium in order to maintain serum potassium concentrations upon administration of the combination of clotting factors and sympathicomimetic agonists alone or in combination with the adrenergic receptor blockers. A third object of the present invention thus relates to a composition comprising a clotting factor, an adrenergic receptor agonist, potassium in a pharmaceutically acceptable form and optionally a beta blocker for the treatment or prophylaxis of bleeding in a subject.

Additional aspects of the present invention and particular embodiments will be apparent from the description below as well from the appended claims.

Brief Description of Drawings Figure 1 : TEG technology. Figure 2: TEG parameters.

Figure 3: Representative TEG profile of healthy volunteers before and after administration of a sympathicomimetics agonist (adrenaline). Figure 4 a, b, and c: TEG parameters (4a) R, (4b) Angle and (4c) MA of 30 healthy volunteers after totally 15 minutes of i.v. administration of adrenaline.

Figure 5: TEG MA measured before and after i.v. infusion of noradrenaline at 4.8 μg/kg/h for 15 minutes in 10 healthy volunteers.

Figure 6: TEG MA measured before (t=0) and after i.v. infusion of adrenaline at 4.8 μg/kg/h for 15 minutes (t=15) and 30 minutes after discontinuation of adrenaline administration (t=45).

Figure 7 a, b and c: TEG parameters (7a) R, (7b) Angle and (7c) MA from blood samples collected from patients infused with adrenaline prior to prostatectomy. Figure 8: Intra-operative bleeding (in ml) of the patients of figure 7 (receiving adrenaline in the step-wise doses 1 , 2 and 3 μg/kg/h) and 10 other prostatectomy patients receiving a 15 minutes continuous adrenaline infusion of 3 μg/kg/h.

Figure 9 a and b: (9a) A representative example of TEG tracings with tPA induced fibrinolysis before and immediately after infusions of adrenaline. (9b) Statistic comparisons of the lysis AUC (area under the curve). Figure 10: Administration of adrenaline and adrenaline and seloken to 7 healthy volunteers.

Figure 11 a, b, c, d, and e: The volunteers of figure 10 were monitored haemodynamically at the same time points as described in figure 10: (1 1a) heart rate (HR), (1 1 b) cardiac output (CO), (11 c) stroke volume (SV), (1 1d) invasive blood pressure: mean arterial pressure, MAP) and (11 e) total peripheral resistance (TPR). Figure 12: Administration of adrenaline in stepwise doses followed by Seloken and again adrenaline in stepwise doses to 7 healthy volunteers. Figure 13: Representative TEG profile of a healthy volunteer before and after administration of a clotting factor (rFVIIa). Figure 14: TEG MA in awake volunteers.

Figure 15: TEG MA in prostatectomy patients during surgery.

Detailed description of the invention Definitions: The term "activity" is intended to mean the ability to generate a clot of improved stability as well as an increased initiation, amplification and propagation of the hemostatic system, resulting in a faster formation of a clot of greater mechanical strength and stability together with increased resistance to fibrinolysis as compared to when the agonists are not administered.

The term "bleeding disorder" used herein will reflect any defect, congenital, acquired or induced, of cellular or molecular origin that is manifested in bleedings. The term "bleeding episodes" or "bleeding" is meant to include any episode were bleeding of a magnitude necessitating administration of blood products may occur, including uncontrolled and excessive bleeding both in connection with surgery and other forms of tissue damage in a subject.

A "subject" or "patient" includes humans and other mammals, and thus the methods are applicable to both human therapy and veterinary applications, in particular to human therapy. The term "mammal" includes humans, non-human primates (e.g. baboons, orangutans, monkeys), mice, pigs, cows, goats, cats, rabbits, rats, guinea pigs, hamsters, horse, monkeys, sheep or other non-human mammal.

Treatment, as used in this application, is therefore intended to include both prevention of an expected bleeding, such as in surgery, and regulation of an already occurring bleeding, such as in trauma, with the purpose of inhibiting or minimizing the bleeding. Prophylactic administration of the variant according to the invention is thus included in the term "treatment". The term clotting factor as used herein further covers any proenzyme / zymogen or activated clotting factor and thus the term "variant hereof" includes both the zymogen and activated form of a given clotting factor. The terms clotting factor and coagulation are used interchangeably. An "a" at the end of the name of a given clotting factor is intended to the activated version of said factor for example: FVIIa is the activated from of FVII.

The terms factor Vila or FVIIa are intended to mean the activated form of clotting factor VII. rFVIIa is intended to mean the recombinant activated form of clotting factor Vl and rhFVIIa is intended to mean the recombinant human activated form of clotting factor VII. NovoSeven™ may be referred to as both rFVIIa and rhFVIIa.

With variant and analogue is also meant any variant and analogue of a clotting factor according to the invention which are functional equivalents of said clotting factors. By the term "functional equivalent" of a clotting factor is in the present context meant a molecule which meets the criteria for a variant or a fragment of said clotting factor described above and which is capable of one or more functional activities of said clotting factor or a compound comprising said clotting factor.

The terms "sympathicomimetics" or "sympathicomimetic agonists" or "adrenergic receptor agonist" are used interchangeable herein, includes any pharmaceutical compounds with the same or similar activity as noradrenaline (norepinephrine) and adrenaline (epinephrine). This group of compounds, having predominantly peripheral action, can be divided into:

• Directly acting sympathicomimetics that acts by stimulating the receptors of the sympathetic nervous system, and

• Indirectly acting sympathicomimetics that act by either releasing transmitters from the prejunctional nerve ends or by inhibiting their removal from the synaptic junction.

The terms "used in combination", "administered in combination with" or "coadministered" or "composition" indicate that the drugs may be formulated together, or are kept as separate entities and may be administered simultaneously or within a predetermined interval of each other. Examples of how the clotting factors, the sympathicomimetic agonists and/or potassium of the present invention may be administered in combination with each other are given in the below.

As used herein, "dose" shall mean any concentration of the clotting factors and agonists administered producing a pro-hemostatic effect on the hemostatic system. A dose sufficient to produce the desired effect in relation to the conditions for which it is administered, in particular an amount of a clotting factor and sympathicomimetic agonists that is effective to stop, reduce or prevent the unwanted bleeding shall be described as the "effective dose", "therapeutically effective dose" or "effective amount". Normally the dose should be capable of preventing or lessening the severity or spread of the condition or indication being treated. The exact dose will depend on the circumstances, such as the condition being treated, the administration schedule, whether the clotting factor and sympathicomimetic agonists is administered alone or in conjunction with another therapeutic agent or another clotting factor or sympathicomimetic agonists, the plasma half-life of the clotting factor and the sympathicomimetic agonists and the general health of the subject.

The terms tachycardia / tachyarrhythmia are intended to mean rapid heart rate, usually defined as greater than 100 beats per minute at rest. The tachycardias include sinus tachycardia, paroxysmal atrial tachycardia (PAT), and ventricular tachycardia..

As used herein, the term "pharmaceutical acceptable" means a carriers or excipients that does not cause any untoward effects in subjects to whom it is administered.

As used herein, the term "trauma" is intended to mean injury to living tissue caused by an extrinsic agent.

It has for many years been known that endogenous sympathetic activation secondary to a stress response results in an increase in procoagulant factors, platelet activation as well as in markers of increased fibrinolysis [Cannon et al. 1914]. Extensive research in athletes have corroborated that physical exercise results in increased levels of circulating sympathetic transmitters and that this is associated with an increased level of activated coagulation factors as well as increased fibrinolysis [Colman et al. 2001]. As mentioned above, sympathicomimetic agonists have been used for a considerable time as a local hemostatic agents due to their well-known vasoconstricting effects on the vasculature whereby bleeding can be reduced through contraction of the peripheral blood vessels.

Due to the effect of these sympathicomimetic agonists on heart rate, blood pressure, anxiety and redistribution of blood flow, they have not been used to stop or prevent bleeding episodes by systemic administration, because at the recommended doses the agonists will cause increased heart rate and blood pressure levels, anxiety and ventricular arrhythmia which together with the increased blood loss through open vessels is unacceptable in the majority of patients.

In WO 2009/043355 it was shown that systemic administration of a very low dose of sympathicomimetic agonists activates the hemostatic system without causing any significant elevation of the blood pressure.

The inventor of the present invention has surprisingly found that the combination of low doses of clotting factors and sympathicomimetic agonists activate the hemostatic system and improve clot strength and stability. By systemic administration of low doses of a combination of clotting factors and sympathicomimetic agonists no significant elevation of the blood pressure is experienced and thereby blood loss due to this effect is absent, whereas the pro-hemostatic effect on the coagulation system is increased. Administration of clotting factors and sympathicomimetic agonists result in a dose- dependent increase in velocity in the initiation phase and in thrombin burst that is more pronounced than what can be achieved with sympathicomimetic agonists alone. This increase in thrombin burst results in a clot that is more resistant against fibrinolysis (LyAUC) than what can be achieved by sympathicomimetic agonists alone, whereas maximal clot strength not is affected. There is thus a synergistic effect between the clotting factors and sympathicomimetic agonists that result in a stronger, more durable clot.

Besides adrenaline, administration of e.g. other sympathicomimetic agonists such as noradrenaline, dopamine, dobutamine, ephedrine etc. (see herein below) is contemplated to lead to a systemic activation of the coagulation system, and importantly, to an improved hemostatic ability in humans due to improved clot strength. The addition of a low dose of clotting factors will result in a faster maximal haemostatic effect. The mechanical strength of the clot is the determining factor for whether hemostasis can be achieved, since the strength of the clot determines if it can resist the shear forces of the flowing blood [Kawasaki et al 2004, Fries et al. 2006, Velik- Salchner et al. 2007, Bassus et al. 2006, Sørensen et al. 2005, Tomokiyo et al. 2003].

Interestingly, despite the speed, strength and durability of the clot formation, thrombosis does not occur more frequently with the agents of the present invention than without administration of the agents. This may in part be due to the fact that the sympathicomimetic agonists such as adrenaline and noradrenaline quickly, as in within minutes, are cleared from the body. Thus, the effects of the sympathicomimetic agonists are halted within minutes of termination of administration, and the hemostatic equilibrium of the particular subject is returned to its usual level. Addition of doses of clotting factors as low as relevant for the present invention also does not increase the risk of thrombosis. Furthermore, the clot is not after formation a permanent feature, the equilibrium between coagulation and fibrinolysis is changed, due to the increased speed of formation and longer durability of the clot following adrenaline administration, but there still is equilibrium between coagulation and fibrinolysis.

The advantages of the present invention are several fold: for the individual subject treated less blood is lost and thus less, if any, blood and/or blood products need be administered. Thus is beneficial to the subject as a reduced blood loss lessens the stress on the bodily systems of the subject and adverse effects known to medical practitioners and others skilled in the art that may follow from receiving blood and/or blood products are avoided and/or minimized. Obviously, with no or only a fraction of the blood / blood products used for a given procedure, money is saved and thus the administration of the combination of clotting factors and sympathicomimetic agonists optionally in combination with potassium as stated in the below has an economic incentive as well.

The present invention is useful in any situation wherein an individual is bleeding e.g. trauma, or is expected to bleed eg. during surgery. These two situations differ in several respects: during trauma, if it is at all possible to administer anesthesia, there is no time to wait for the full effect before performing the necessary interventions; during elective surgery, which here is defined as any type of non-acute intervention that will or is expected to cause bleeding, the entire situation is under control from the onset, and there is time to wait for the full effect of the anesthesia to set in. When a patient is fully anesthetized the blood pressure generally lowers. Surprisingly the inventor has found that fully anesthetized patients require less sympathicomimetic agonist for the treatment to be effective: e.g: 3 - 3.5 μg/kg of adrenaline in combination with a clotting factor is sufficient for the full effect of the treatment, whereas 5-6 μg/kg of adrenaline in combination with a clotting factor is required in non-anesthetized patients, please see Figures 14 and 15 showing TEG MA results for awake volunteers (Figure 14) and anesthetized patients undergoing prostatectomy (Figure 15).

The present invention is particularly useful for the treatment of trauma, especially in a pre-hospital setting, where blood loss before entering the hospital is the major determinant of mortality.

The term "activity" is intended to mean the ability to generate a clot of improved stability as well as an increased initiation, amplification and propagation of the hemostatic system, resulting in a faster formation of a clot of greater mechanical strength and stability together with increased resistance to fibrinolysis as compared to when the agonists are not administered.

The clinical importance of clot strength for hemostasis has further been illustrated in postoperative patients with ongoing bleedings, where a normalization of clot strength was associated with achievement of hemostasis [Johansson Pl. 2007]. Patients with reduced clot strength, as evidenced by a reduced TEG MA (TEG: thrombelastography, MA: maximal amplitude), where treated with infusion of platelets until a normalization of clot strength, i.e. TEG MA was found, correlating with achievement of hemostasis. See Example 1 for a review of the TEG technology.

It is therefore envisaged that systemic administration of a combination of clotting factors and sympathicomimetic agonists, will be useful for treatment or prophylaxis of controlled or uncontrolled bleeding episodes in connection with various forms of e.g. trauma, surgery, post partum or due to congenital or acquired bleeding conditions.

Administration of the sympathicomimetic agonists of the present invention increases clot strength and stability and may be used to increase the clot strength and stability in a subject with subnormal clot strength and stability or may be used to increase clot strength and stability in a subject with normal clot strength and stability to a higher degree of strength and stability. Thus, clot strength and stability is shifted to a more stable level following administration of a combination of clotting factors and sympathicomimetic agonists. Preferably, the clot strength and stability after administering a combination of the clotting factor(s) and the sympathicomimetic agonist(s) is kept within the normal range of clot strength and stability but is either lifted from a subnormal level to within the normal range of clot strength and stability or is lifted from within the normal range of clot strength and stability towards the upper end of the normal range of clot stability. By staying within the normal range of clot strength and stability possible adverse effects are not encountered. Thus it is an object of the present invention that the clot strength and/or stability by administration of a combination of a clotting factor and a sympathicomimetic agonist is shifted to the upper end of the normal range(s) of clot strength and /or stability. It is an option to further use the combination of a clotting factor and a sympathicomimetic agonist together with a beta blocker in any of the herein cited embodiments.

The clot strength and stability and changes herein may be measured as increases in relative clot strength by the TEG (Thrombelastography) measurable parameter MA and clot stability by the TEG derivable parameter Lysis AUC. The maximal amplitude (MA) parameter reflects maximal clot strength i.e. the maximal elastic modus of the clot. The area under the lysis curve, i.e. area under the curve from MA is obtained (Lysis AUC) reflects degree of fibrinolysis (see Figure 2). Both clot strength and stability may be measured, or one parameter only may be followed during a procedure such as either the clot stability or the clot strength. It is an object of the present invention that the clot strength measured by the MA increases relative to the MA prior to administration of a sympathicomimetic agonist by 105%, such as by 1 10%, such as by 115%, such as by 120%, such as by 125%, such as by 130%, such as by 135%, such as by 140%, such as by 145%, such as by 150%, such as by 155%, such as by 160%, such as by 165%, such as by 170%, such as by 175%, such as by 180%, such as by 185%, such as by 190%, such as by 195%, such as by 200% or more. Likewise it is an object of the present invention that the clot stability increases Lysis AUC. This parameter may with a TEG analysis be measured e.g. after addition of tissue plasminogen activator (tPA), and thus it is an object of the present invention that the clot stability measured by the Lysis AUC increases relative to the Lysis AUC prior to administration of a sympathicomimetic agonist by 105%, such as by 1 10%, such as by 115%, such as by 120%, such as by 125%, such as by 130%, such as by 135%, such as by 140%, such as by 145%, such as by 150%, such as by 155%, such as by 160%, such as by 165%, such as by 170%, such as by 175%, such as by 180%, such as by 185%, such as by 190%, such as by 195%, such as by 200% or more.

Additional values that represent clot formation as determined by TEG (Thrombelastography) are: the R value (or reaction time), the K value, and the angle (and as stated above the MA (maximum amplitude)). The R value represents the speed of clot formation (time until the first evidence of a clot is detected). The K value is the time from the end or R until the clot reaches 20mm and this represents the speed of clot formation. The angle is the tangent of the curve made as the K is reached and offers similar information to K.

The R value is of special relevance when administering coagulation factors, as the addition of a coagulation factor decreases the R value as measured by TEG. Therefore it is an object of the present invention that the R value decreases relative to the measurement of the R value prior to administration of one or more coagulation factors optionally in combination with a sympathicomimetic agonist (and optionally further in combination with a beta blocker) by anywhere between 1 and 99% such as by 5%, such as by 10%, such as by 15%, such as by 20%, such as by 25%, such as by 30%, such as by 35%, such as by 40%, such as by 45%, such as by 50%, such as by 55%, such as by 60%, such as by 65%, such as by 70%, such as by 75%, such as by 80%, such as by 85%, such as by 90% such as by 95%, such as by 98%.

Likewise, the Angle value is of special relevance when administering coagulation factors, as the addition of a coagulation factor increases the Angle value as measured by TEG. Therefore it is an object of the present invention that the Angle value increases relative to the measurement of the Angle value prior to administration of one or more coagulation factors optionally in combination with a sympathicomimetic agonist (and optionally further in combination with a beta blocker) 105%, such as by 110%, such as by 1 15%, such as by 120%, such as by 125%, such as by 130%, such as by 135%, such as by 140%, such as by 145%, such as by 150%, such as by 155%, such as by 160%, such as by 165%, such as by 170%, such as by 175%, such as by 180%, such as by 185%, such as by 190%, such as by 195%, such as by 200% or more. As follows from the above, disregarding which level of strength or stability is achieved, once the administration of the combination of the clotting factor and the sympathicomimetic agonist stops, the levels will return to their pre-administrative levels, due to the rapid break down / turn over of the clotting factor and sympathicomimetic agonist.

Treatment, as used in this application, is therefore intended to include both prevention of an expected bleeding, such as in surgery, and regulation of an already occurring bleeding, such as in trauma, with the purpose of inhibiting or minimizing the bleeding. Prophylactic administration of the variant according to the invention is thus included in the term "treatment".

Clotting factors

Blood coagulation is a process consisting of a complex interaction of various blood components (or factors) that eventually gives rise to a fibrin clot [Roberts et al. 2006]. Generally, the blood components, which participate in what has been referred to as the coagulation "cascade", are enzymatically inactive proteins (proenzymes or zymogens) that are converted to proteolytic enzymes by the action of an activator (which itself is an activated clotting factor). Clotting factors that have undergone such a conversion are generally referred to as "active factors", and are designated by the addition of the letter "a" to the name of the clotting factor. The term clotting factor as used herein further covers any proenzyme / zymogen or activated clotting factor and thus the term "variant hereof" includes both the zymogen and activated form of a given clotting factor.

An object of the present invention is the use of low doses of clotting factors in combination with low doses of sympathicomimetic agonists for the treatment and/or prophylaxis of bleeding in a subject.

A clotting factor for use according to the present invention may be any clotting factor including any variant or analogue with the same or similar activity as activated factor VII (FVIIa), or any pharmaceutical compound containing a clotting factor or variants or analogues. The term "factor VII" is intended to encompass, without limitation, polypeptides having the amino acid sequence 1-406 of wild-type human factor VII (as disclosed in U. S. Patent No. 4,784, 950 or NP_000122), as well as wild-type factor Vl I derived from other species, such as, e. g., bovine, porcine, canine, murine, and salmon factor VII, said factor VII derived from blood or plasma, or produced by recombinant means. It further encompasses natural allelic variations of factor VII that may exist and occur from one individual to another. Also, degree and location of glycosylation or other post-translation modifications may vary depending on the chosen host cells and the nature of the host cellular environment. The term "factor VII" is also intended to encompass factor VII polypeptides in their uncleaved (zymogen) form, as well as those that have been proteolytically processed to yield their respective bioactive forms, which may be designated factor Vila. Typically, factor VII is cleaved between residues 152 and 153 to yield factor Vila.

Variant of clotting factors relevant to the present invention also include as herein exemplified by variants of FVII and FVIIa genetically modified versions of a clotting factor such as the V158D/E296V/M298Q (NN1731 ) form of FVII or any GIa domain variants of human Factor VII or human Factor Vila, comprising 1-15 amino acid modifications relative to human Factor VII or human Factor Vila, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36 such as disclosed in US 20071 17756. All variants disclosed herein are incorporated by reference. Variants also include conjugates of Factor VII (FVII) and Factor Vila (FVIIA), wherein a conjugate comprises at least one non-polypeptide moiety covalently attached to a polypeptide of FVII or FVIIa as disclosed in US 2009023635 and hereby incorporated by reference. Non limiting examples of clotting factors according to the present invention include, but are not limited to: clotting factors I (fibrinogen), Il (prothrombin), Tissue factor, Calcium, V (proaccelerin, labile factor), Vl, VII (stable factor), VIII (Anti Hemophilic factor A,), IX (Anti Hemophilic Factor B or Christmas factor, NP_000124 or P00740), X (Stuart- Prower factor, NP_000495 or P00742), Xl (plasma thromboplastin antecedent), XII (Hageman factor), XIII (fibrin-stabilizing factor, A1 polypeptide: NM_000129 or P00488; B polypeptide: NM_001994 or P05160), von Willebrand factor, prekallikrein, high- molecular-weight kininogen (HMWK), and fibronectin, and any activated form of any of the mentioned clotting factors.

Furthermore, it is within the scope of the present invention that a combination of clotting factors may be used as is commercially available in specific concentrates. Thus, a clotting factor for use according to the present invention may be a prothrombin complex concentrate factor and/or an activated prothrombin complex concentrate factor. Such concentrates may include FII, FVII , FIX and FX as for example Octaplex and Beriplex as well as preparations comprising the activated factors FIIa, FVIIa , FIa, and FXa, such as FIEBA. Other relevant commercially available products include, but are not limited to: recombinant FVIII such as Advate, Nexgene, Kogenate, Refakto and human derived products such as Haemate, and Octanate. Others include recombinant human factor Vila (rhFVIIa) (NovoSeven), a fibrinogen-concentrate (Haemocomplettan), human FXIII (Fibrogammin-P) and recombinant FXIII.

Preferably a clotting factor for use according to the invention is selected from the group comprising the activated forms of the clotting factors FVIIa, rFVIIa, rhFVIIa, FXIIIa,

FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

Activated clotting factors are preferred over the non-activated forms. Thus FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof are more preferred. More preferably the clotting factor is selected from the group consisting of FVIIa, FXIIIa, FIXa and FXa or a variant or analogue thereof. More preferably the clotting factor for use according to the invention is selected from the group comprising FVIIa, rFVIIa, rhFVIIa, FVII, rFVII, or a variant or analogue thereof.

Most preferably the clotting factor for use according to the invention is FVIIa, rFVIIa, rhFVIIa or a variant or analogue thereof.

The clotting factors for use according to the invention may be a natural clotting factor and/or a recombinant clotting factor. Recombinant FVIIa (rFVIIa) and human recombinant FVIIa (rhFVIIa) are preferred. Most preferred is NovoSeven™ or any other brand on the market.

The clotting factors may also be in combination of two or more, such as three or more, such as four or five or more of any of the clotting factors discussed above.

With variant and analogue is meant a protein that has a level of amino acid identity with the naturally occurring clotting factor an amino acid sequence which has at least 75% identity with a sequence of a selected clotting factor, such as 76-80% identity, for example 81-85% identity, such as 86-90% identity, for example 91-95% identity, such as 96-99% identity, wherein the identity is defined as a percentage of identical amino acids in said sequence when it is collated with the selected sequence. The identity between amino acid sequences may be calculated using well known algorithms such as BLOSUM 30, BLOSUM 40, BLOSUM 45, BLOSUM 50, BLOSUM 55, BLOSUM 60, BLOSUM 62, BLOSUM 65, BLOSUM 70, BLOSUM 75, BLOSUM 80, BLOSUM 85, or BLOSUM 90. A variant and analogue according to the invention can be a recombinant or non-recombinant amino acid sequence.

With variant and analogue is also meant any variant and analogue of a clotting factor according to the invention which are functional equivalents of said clotting factors. By the term "functional equivalent" of a clotting factor is in the present context meant a molecule which meets the criteria for a variant or a fragment of said clotting factor described above and which is capable of one or more functional activities of said clotting factor or a compound comprising said clotting factor. The functionality of a clotting factor according to the present invention may be assessed in several ways. For example, any clotting factor or compound capable of inducing an activation of the hemostatic system equal to or better than that of 1 to 100 microgram/kg of FVIIa is contemplated to induce a significant pro-hemostatic effect and is thus falls within the scope of the present invention.

Furthermore, any clotting factor or compound capable of inducing an activation of the hemostatic system equal to or better than that of between 1 and 10 microgram/kg/hour of adrenaline is contemplated to induce a significant pro-hemostatic effect. Thus it follows, that any clotting factor or compound capable of inducing an activation of the hemostatic system equal to that of 6 microgram/kg/hour of adrenaline is contemplated to induce a significant pro-hemostatic effect.

Any clotting factor able of inducing an activation of the hemostatic system equal to or better than that of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline is contemplated to induce a significant pro-hemostatic effect. Thus, a method for testing the hemostatic efficacy and/or the required dose of a clotting factor comprises the following steps: a) administering to a subject and/or to a blood sample taken from a subject a clotting factor to be tested, b) optionally administering a sympathicomimetic agonist and/or a beta blocker prior to, during or after administering the clotting factor to the subject or to a sample of venous or arterial blood from the subject, c) conducting a TEG analysis on a blood sample from the subject, d) comparing the at least one measured parameter such as but not limited to: R value (clotting time), K value (clot kinetics), Angle or alpha (representing velocity of clot formation), MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the intravenous administration of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline, wherein the parameters obtained for the 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline may be obtained from the same subject being tested with the clotting factor or a reference value / parameter obtained in advance. Preferably, a clotting factor is tested against the values obtained for FVIIa, such as for 5 microgram/kg of FVIIa, 10 microgram/kg of FVIIa or any concentration of FVIIa between 1 and 100 microgram/kg.

Preferably, the parameter measured is R value (clotting time). A preferred clotting factor is capable of reducing the R value of the blood also when administered in combination with a sympathicomimetic agonist or when administered with both a sympathicomimetic agonist and a beta blocker. Also, a preferred clotting factor is capable of increasing the Angle value of the blood also when administered in combination with a sympathicomimetic agonist or when administered with both a sympathicomimetic agonist and a beta blocker. A most preferred clotting factor is capable of both reducing the R value and increasing the Angle value of the blood also when administered in combination with a sympathicomimetic agonist or when administered with both a sympathicomimetic agonist and a beta blocker.

In an embodiment the lowest dosage of clotting factor administered gives a response corresponding to that measured upon the administration of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline, optionally this response is measured in one of the assays herein disclosed.

In an embodiment the lowest dosage of clotting factor administered gives a response corresponding to that measured upon the administration of 6 microgram/kg/hour of adrenaline; preferably, the clotting factor is FVIIa, optionally this response is measured in one of the assays as herein disclosed.

By reference value is understood a value that has been obtained after repeated testing of the effects of administering either 5 microgram/kg of FVIIa or 6 microgram/kg/hour of adrenaline to a statistically relevant number of subjects. The reference value may alternatively be based on the effects of administering another concentration of FVIIa, such as but not limited to: between 5 microgram/kg of FVIIa and 100 microgram/kg of FVIIa, dependent upon which effect is desired to be achieved by the clotting factor, such a concentration may be 2 microgram/kg, such as 3 microgram/kg/hour, such as 5 microgram/kg, such as 6 microgram/kg/hour, such as 9 microgram/kg/hour, such as 10 microgram/kg, such as 12 microgram/kg/hour, such as 15 microgram/kg, such as 20 microgram/kg, such as 25 microgram/kg, such as 30 microgram/kg, such as 35 microgram/kg, such as 40 microgram/kg, such as 45 microgram/kg, such as 50 microgram/kg, such as 55 microgram/kg, such as 60 microgram/kg, such as 65 microgram/kg, such as 70 microgram/kg, such as 75 microgram/kg, such as 80 microgram/kg, such as 85 microgram/kg, such as 90 microgram/kg, such as 95 microgram/kg of FVIIa. Or as is relevant for the second assay: between 1 microgram/kg/hour of adrenaline and 15 microgram/kg/hour of adrenaline, dependent upon which effect is desired to be achieved by the clotting factor, such a concentration may be 2 microgram/kg/hour, such as 3 microgram/kg/hour, such as 6 microgram/kg/hour, such as 9 microgram/kg/hour, such as 12 microgram/kg/hour, such as 15 microgram/kg/hour of adrenaline.

The method for testing the hemostatic efficacy and/or the required dose of a clotting factor may optionally comprise an additional step relating to from where the blood sample from the subject is collected, namely whether it is collected from an artery or a vein and dependent hereon, the sample(s) on which the reference value(s) is / are based must have been collected from the same arterial or venous source to ensure accuracy.

Thus, in one aspect of the present invention the blood sample to be analyzed and the sample or samples (such as those on which a reference value is based) with which it is compared are all drawn from arterial blood.

In another aspect of the present invention the blood sample to be analyzed and the sample or samples (such as those on which a reference value is based) with which it is compared are all drawn from venous blood.

Therefore it follows that the method for testing the hemostatic efficacy and/or the required dose of a clotting factor may further comprise the following steps: a) administering to a subject and/or to a venous or arterial blood sample taken from a subject a clotting factor to be tested, b) optionally administering a sympathicomimetic agonist and/or a beta blocker prior to, during or after administering the clotting factor to the subject or to a sample of venous or arterial blood from the subject, c) conducting a TEG analysis on a blood sample from the subject, d) comparing the at least one measured parameter such as but not limited to: R value (clotting time), K value (clot kinetics), Angle or alpha (representing velocity of clot formation) MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the administration of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline as measured on a venous or arterial blood sample, the sample being drawn from the same source as in a) wherein the parameters obtained for the 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline may be obtained from the same subject being tested with the clotting factor or a reference value / parameter obtained in advance.

Preferably, a clotting factor is tested against the values obtained for FVIIa, such as for 5 microgram/kg of FVIIa, 10 microgram/kg of FVIIa or any concentration of FVIIa between 1 and 100 microgram/kg.

By reference value is understood a value as indicated in the above.

It is understood that in any of the assays given herein the compounds including those that give the reference value(s) i.e. FVIIa and/or adrenaline may be administered to a subject prior to or while drawing blood and as a single or repeated bolus or continuous infusion or during or after sampling of the blood where the compound(s) is/are administered to the sample directly.

Preferably, a clotting factor for use according to the present invention is a substance capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as: lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength), increasing the Lysis AUC (the area under the fibrinolysis curve AUC) and/or increasing the fibrinolysis time (LY). Preferably, a clotting factor for use according to the present invention is a substance capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength). Most preferably, a clotting factor for use according to the present invention is a substance capable of altering the lowering the r value (clotting time) and/or increasing the Angle value.

Sympathicomimetic agonists

As apparent from the above, the treatment with the combination of clotting factors and sympathicomimetic agonists according to the present invention comprises adrenaline, noradrenaline, dobutamin, ephedrine, dopamine etc, see herein below. However, it is envisaged that the "sympathicomimetics" or "sympathicomimetic agonists" or "adrenergic receptor agonist" as used interchangeably herein, includes any pharmaceutical compounds with the same or similar activity as noradrenaline (norepinephrine) and adrenaline (epinephrine). This group of compounds, having predominantly peripheral action, can be divided into:

Directly acting sympathicomimetics act upon the adrenergic receptors (adrenoceptors), these comprising the a_r, a₂-, βi, β₂- and β₃-subtypes [Goldstein. 2006]. Any sympathicomimetic agonist is of relevance for the present invention for use in the treatment and/or prophylaxis of bleeding in a subject. Such sympathicomimetic agonists include but are not limited to agonists that are ligands of any one or more of the abovementioned receptors. Some sympathicomimetic agonists are specific for one or more of the abovementioned receptors; for example a particular agonist may be alpha-1 specific, or be alpha specific indicating that the agonist will bind either of the two known alpha receptors, or may be an agonist capable of interacting with any of the adrenergic receptors; an example hereof is adrenaline. Examples of all of these types of sympathicomimetic of relevance to the present invention include, but are not limited to: Adrenaline (epinephrine), Noradrenaline (norepinephrine), Phenylephrine, Methoxamine, Cirazoline, Xylometazoline, Methylnorepinephrine, Oxymetazoline, Dexmedetomidine, Clonidine, Lofexidine, Xylazine, Tizanidine, Guanfacine, Guanabenz, Guanoxabenz, Guanethidine, Methyldopa, amidephrine, amitraz, anisodamine, apraclonidine, brimonidine, cirazoline, detomidine, dexmedetomidine, ergotamine, etilefrine, indanidine, lofexidine, medetomidine, mephentermine, metaraminol (e.g. Aramine), methoxamine, midodrine, mivazerol, naphazoline, norfenefrine, octopamine, oxymetazoline, phenylpropanolamine, rilmenidine, romifidine, synephrine, talipexole and tizanidine, Dopamine (e.g. Intropine) Dobutamine, Dobutrex, Isoproterenol, Salbutamol (Albuterol in USA), Bitolterol mesylate, Formoterol, Isoprenaline, Levalbuterol, Metaproterenol, Salmeterol, Terbutaline, Ritodrine, Fenoterol, Clenbuterol, L-796568, Amibegron, Solabegron, arbutamine, befunolol, bromoacetylalprenololmenthane, broxaterol, cimaterol, cirazoline, denopamine, dopexamine, etilefrine, hexoprenaline, higenamine, isoetharine, isoxsuprine, mabuterol, methoxyphenamine, nylidrin, oxyfedrine, pirbuterol, prenalterol, procaterol, ractopamine, reproterol, rimiterol, ritodrine, tretoquinol, tulobuterol, xamoterol, and zinterol. Brand names of these compounds may vary from company to company and country to country; aliases of the abovementioned compounds or other sympathicomimetic agonists are included within the scope of the present invention.

Preferably, sympathicomimetic agonists for use according to the invention comprises agonists of the Alpha-1 adrenergic receptor, such as but not limited to: Adrenaline (epinephrine), Noradrenaline (norepinephrine), Phenylephrine, Methoxamine, Cirazoline, Xylometazoline Methylnorepinephrine, and Oxymetazoline; as well as Alpha-2 adrenergic receptor agonists such as, but not limited to: Adrenaline (epinephrine), Noradrenaline (norepinephrine), Dexmedetomidine, Clonidine, Lofexidine, Xylazine, Tizanidine, Guanfacine, Guanabenz, Guanoxabenz,

Guanethidine, and Methyldopa; and agonists that interact with both alpha receptors (and in some instances also the beta receptors), examples of these including, but again not being limited to: Adrenaline (epinephrine), Noradrenaline (norepinephrine), amidephrine, amitraz, anisodamine, apraclonidine, brimonidine, cirazoline, detomidine, dexmedetomidine, ergotamine, etilefrine, indanidine, lofexidine, medetomidine, mephentermine, metaraminol, methoxamine, midodrine, mivazerol, naphazoline, , norfenefrine, octopamine, oxymetazoline, phenylpropanolamine, rilmenidine, romifidine, synephrine, talipexole and tizanidine. Likewise, examples of sympathicomimetic agonists that according to the present invention may be administered for the prevention and/or treatment of bleeding in a subject are agonists that interact with the beta receptors, these include, but are not limited to agonists that bind the Beta 1 adrenergic receptor, such as, but not restricted to: Noradrenaline, Isoprenaline, Dobutamine, Dobutrex, and Isoproterenol (β1 and β2); the Beta-2 adrenergic receptor agonists, again including but not limited to: Salbutamol (Albuterol in USA), Bitolterol mesylate, Formoterol, Isoprenaline, Levalbuterol, Metaproterenol, Salmeterol, Terbutaline, Ritodrine, Fenoterol, Isoproterenol (β1 and β2), and Clenbuterol; as well as the following non-limiting examples of agonists that bind the Beta-3 adrenergic receptor: L-796568, Amibegron, Solabegron,

Noradrenaline, adrenaline, and isoprenaline; and the sympathicomimetic agonists that may bind either of the beta receptors (and in some cases also the alpha receptors), that list including but not being restricted to: arbutamine, befunolol, bromoacetylalprenololmenthane, broxaterol, cimaterol, cirazoline, denopamine, dopexamine, epinephrine, etilefrine, hexoprenaline, higenamine, isoetharine, isoxsuprine, mabuterol, methoxyphenamine, nylidrin, oxyfedrine, pirbuterol, prenalterol, procaterol, ractopamine, reproterol, rimiterol, ritodrine, tretoquinol, tulobuterol, xamoterol, and zinterol.

The sympathicomimetic agonists for use according to the invention may be any endogenous or exogenous agonistic substance affecting any one or more of the αi, α₂, βi, β₂, ββ adrenergic receptors. Furthermore, the agonistic substance may comprise any human, non-human, recombinant or by any other means manufactured agonistic substance affecting any one or more of the αi, α₂, βi, β₂, ββ adrenergic receptors of the sympathetic nerve system.

Preferably, sympathicomimetic agonists for the prevention and/or treatment of bleeding in a subject include but are not limited to agonists capable of binding at least one adrenergic receptor subtype.

Most preferably the sympathicomimetic agonists for the prevention and/or treatment of bleeding in a subject include but are not limited to adrenaline, noradrenaline, dobutamin, dobutrex, and dopamine, as well as metabolic products and chemically related synthetic derivates hereof. Thus, sympathicomimetic agonists may further include any agonist with an agonistic effect on α-adrenergic and/or β-adrenergic receptors, including any subtypes (e.g. a_r, 0₂-, βi, β₂- and β₃-subtypes), of the sympathetic nervous system, such as but not limited to adrenaline, noradrenaline, dopamine, dobutamin, dobutrex, ephedrine and other known or yet undiscovered chemical or biological substances or compounds where any of the above mentioned are included.

The agonistic substance or derivatives hereof may also be in a combination of two or more, such as three or more, four or more and five or more of any of the sympathicomimetics agonist discussed above.

In a specific embodiment of the present invention, the sympathicomimetic agonists comprise adrenaline and/or noradrenaline and/or dobutamine. Analogs of these substances may also be useful in the present invention.

In a still further embodiment of the present invention, the sympathicomimetic agonist comprises or is adrenaline (epinephrine).

In a still further embodiment of the present invention, the sympathicomimetic agonist comprises or is noradrenaline (norepinephrine).

The terms adrenaline and epinephrine are used interchangeably herein and both denote the compound defined in formula I with IUPAC name: (7?,)-4-(1-hydroxy-2- (methylamino)ethyl)benzene-1 ,2-diol: Formula I:

Likewise, the terms noradrenaline and norepinephrine are used interchangeably herein and both denote the compound defined in formula Il with IUPAC name: 4-(2-Amino-1 - hydroxyethyl)benzene-1 ,2-diol: Formula II:

Any sympathicomimetic able of inducing an activation of the hemostatic system equal to the 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of FVIIA is contemplated to induce a significant pro-hemostatic effect. Thus, a method for testing the hemostatic efficacy and/or the required dose of a sympathicomimetic agonist comprises the following steps: a) administering to a subject and/or to a blood sample taken from a subject a sympathicomimetic agonist to be tested, b) conducting a TEG analysis on a blood sample from the subject, c) comparing the at least one measured parameter such as but not limited to: r value (clotting time), k value (clot kinetics), Angle or alpha (representing velocity of clot formation) MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the administration of 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of FVIIA, wherein the parameters obtained for the 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of FVIIA may be obtained from the same subject being tested with the sympathicomimetic agonist or a reference value / parameter obtained in advance.

By reference value is understood a value that has been obtained after repeated testing of the effects of administering 6 microgram/kg/hour of adrenaline to a statistically relevant number of subjects. The reference value may alternatively be based on the effects of administering another concentration of adrenaline, such as but not limited to: between 1 microgram/kg/hour of adrenaline and 10 microgram/kg/hour of adrenaline, dependent upon which effect is desired to be achieved by the sympathicomimetic agonist.

The method for testing the hemostatic efficacy and/or the required dose of a sympathicomimetic agonist may optionally comprise an additional step relating to from where the blood sample from the subject is collected, namely whether it is collected from an artery or a vein and dependent hereon, the sample(s) on which the reference value(s) is / are based must have been collected from the same arterial or venous source to ensure accuracy.

Therefore it follows that the method for testing the hemostatic efficacy and/or the required dose of a sympathicomimetic agonist may further comprise the following steps: a) administering to a subject and/or to a venous or arterial blood sample taken from a subject a sympathicomimetic agonist to be tested, b) conducting a TEG analysis on a blood sample from the subject, c) comparing the at least one measured parameter such as but not limited to: R value (clotting time), K value (clot kinetics), Angle or alpha (representing velocity of clot formation) MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the administration of 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of

FVIIA as measured on a venous or arterial blood sample, the sample being drawn from the same source as in a) wherein the parameters obtained for the 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of FVIIA may be obtained from the same subject being tested with the sympathicomimetic agonist or a reference value / parameter obtained in advance.

By reference value is understood a value that has been obtained after repeated testing of the effects of administering 6 microgram/kg/hour of adrenaline and/or 5 microgram/kg of FVIIA to a statistically relevant number of subjects. Preferably, a sympathicomimetic agonist for use according to the present invention is a substance capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as: lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha

(representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength), increasing the Lysis AUC (the area under the fibrinolysis curve AUC) and/or decreasing the fibrinolysis 30 min after MA (LY30). Preferably, a sympathicomimetic agonist for use according to the present invention is a substance capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as lowering the r value (clotting time), lowering the k value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength). Most preferably, a sympathicomimetic agonist for use according to the present invention is a substance capable of altering all of the following TEG measurable parameters of the blood of a subject to which the substance is administered by lowering the R value (clotting time), lowering the K value (clot kinetics), and increasing the MA, maximal amplitude, (the maximal physical clot strength).

In this manner it has been found, that noradrenaline may be administered in the same dose interval as adrenaline, and dopamine at a dose of 10 -100 x higher (for example 30 - 300 microgram/kg/hour) than adrenaline and noradrenaline, and dobutamin may be administered at a dose of 10 -100 x higher (for example 30-300 microgram/kg/hour) than adrenaline and noradrenaline.

Combination of clotting factor and sympathicomimetic agonist

An aspect of the present invention relates to the administration of a clotting factor in combination with a sympathicomimetic agonist for treatment/and or prophylaxis of bleeding in a subject.

Systemic administration of adrenaline results in an earlier increase in platelet count and clot strength (MA), as evaluated by TEG than in coagulation factor activity, which increases progressively secondary to increase in circulating coagulation factors and occurs as evaluated by a reduction in APTT (activated partial thromboplastin time), PT (prothrombin time) and a reduction in R as evaluated by TEG. The maximal pro- haemostatic effect of adrenaline occurs after approximately 15-30 min when the maximal coagulation factor activity and platelet reactivity occurs. With the addition of a single low dose rFVIIa at the start of adrenaline infusion (1-20 μg/kg) the initiation of the coagulation process including the thrombin burst will occur earlier than when adrenaline is administered alone and this will result in a faster maximal haemostatic effect. Furthermore, by adding rFVIIa a more pronounced initiation and generation of thrombin burst may be achieved than when adrenaline is administered alone, also when the maximal effect of adrenaline on coagulation factors is present.

Preferably any combination of the clotting factors and sympathicomimetic agonists discussed in the above can be used according to the present invention.

More preferably the clotting factor for use according to the invention is selected from the group consisting of FII, FV, FVII, FVIII, FIX, FX, FXII, FXIII, and FIIa, FVa, FVIIa, FVIIIa, FIXa, FXa, FXIIa and FXIIIa, rFVIIa and rhFVIIa or a variant or analogue thereof, and the sympathicomimetic agonist for use according to the invention is selected from adrenaline, noradrenaline, dobutamin, dobutrex, and dopamine, as well as metabolic products and chemically related synthetic derivates hereof.

Most preferably the clotting factor for use according to invention is FVIIa, rFVIIa, rhFVIIa or a variant or an analogue hereof and the sympathicomimetic agonist for use according to the invention is adrenaline and or/noradrenaline.

Any combination of clotting factors and sympathicomimetic agonists can comprise one or several clotting factors and/or one or several sympathicomimetic agonists.

Likewise, the combination of clotting factor and sympathicomimetic agonist may be administered as bolus injections, repeated bolus injections or continuous injections and may be administered differently from one another such as by administering the sympathicomimetic agonist by continuous infusion and the clotting factor as a single or repeated bolus injections. The timing may also vary such that the administration of a clotting factor may be done prior to, during or after the administration of the sympathicomimetic agonist. Any combination of a clotting factor and a sympathicomimetic agonist able of inducing an activation of the hemostatic system equal to or better than that of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline, is contemplated to induce a significant pro-hemostatic effect. Thus, a method for testing the hemostatic efficacy and/or the required dose(s) of a combination of a clotting factor and a sympathicomimetic agonist comprises the following steps: a) administering to a subject and/or to a blood sample taken from a subject independently of each other or simultaneously a combination of a clotting factor and a sympathicomimetic agonist to be tested, b) conducting a TEG analysis on a blood sample from the subject, c) comparing the at least one measured parameter such as but not limited to: R value (clotting time), K value (clot kinetics), Angle or alpha (representing velocity of clot formation) MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the administration of 1 microgram/kg of FVIIa, and/or 6 microgram/kg/hour of adrenaline wherein the parameters obtained for the 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline may be obtained from the same subject being tested with the combination of a clotting factor and a sympathicomimetic agonist or a reference value / parameter obtained in advance.

By reference value is understood a value that has been obtained after repeated testing of the effects of administering either 5 microgram/kg of FVIIa or 6 microgram/kg/hour of adrenaline to a statistically relevant number of subjects. The reference value may alternatively be based on the effects of administering another concentration of FVIIa, such as but not limited to: between 1 microgram/kg of FVIIa and 100 microgram/kg of FVIIa, dependent upon which effect is desired to be achieved by the clotting factor, such a concentration may be 2 microgram/kg, such as 3 microgram/kg/hour, such as 4 microgram/kg/hour, such as 5 microgram/kg, such as 6 microgram/kg/hour, such as 7 microgram/kg/hour, such as 8 microgram/kg/hour, such as 9 microgram/kg/hour, such as 10 microgram/kg, such as 11 microgram/kg/hour, such as 12 microgram/kg/hour, such as 13 microgram/kg/hour, such as 14 microgram/kg/hour, such as 15 microgram/kg, such as 16 microgram/kg/hour, such as 17 microgram/kg/hour, such as 18 microgram/kg/hour, such as 19 microgram/kg/hour, such as 20 microgram/kg, such as 21 microgram/kg/hour, such as 22 microgram/kg/hour, such as 23 microgram/kg/hour, such as 24 microgram/kg/hour, such as 25 microgram/kg, such as 26 microgram/kg/hour, such as 27 microgram/kg/hour, such as 28 microgram/kg/hour, such as 29 microgram/kg/hour, such as 30 microgram/kg, such as 35 microgram/kg, such as 40 microgram/kg, such as 45 microgram/kg, such as 50 microgram/kg, such as 55 microgram/kg, such as 60 microgram/kg, such as 65 microgram/kg, such as 70 microgram/kg, such as 75 microgram/kg, such as 80 microgram/kg, such as 85 microgram/kg, such as 90 microgram/kg, such as 95 microgram/kg of FVIIa. Or as is relevant for the second assay: between 1 microgram/kg/hour of adrenaline and 15 microgram/kg/hour of adrenaline, dependent upon which effect is desired to be achieved by the clotting factor, such a concentration may be 2 microgram/kg/hour, such as 3 microgram/kg/hour, such as 6 microgram/kg/hour, such as 9 microgram/kg/hour, such as 12 microgram/kg/hour, such as 15 microgram/kg/hour of adrenaline.

The method for testing the hemostatic efficacy and/or the required dose(s) of a combination of a clotting factor and a sympathicomimetic agonist may optionally comprise an additional step relating to from where the blood sample from the subject is collected, namely whether it is collected from an artery or a vein and dependent hereon, the sample(s) on which the reference value(s) is / are based must have been collected from the same arterial or venous source to ensure accuracy.

Therefore it follows that the method for testing the hemostatic efficacy and/or the required dose of a clotting factor or a combination of a clotting factor and a sympathicomimetic agonist optionally also combined with a beta blocker may further comprise the following steps: a) administering to a subject and/or to a venous or arterial blood sample taken from a subject independently of each other or simultaneously a clotting factor or a combination of a clotting factor and a sympathicomimetic agonist optionally also combined with a beta blocker to be tested, b) conducting a TEG analysis on a blood sample from the subject, c) comparing the at least one measured parameter such as but not limited to: R value (clotting time), K value (clot kinetics), Angle or alpha (representing velocity of clot formation) MA, maximal amplitude, (the maximal physical clot strength), Lysis AUC (the area under the fibrinolysis curve AUC) and/or fibrinolysis time (LY) with the same one or more parameters following the administration of 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline as measured on a venous or arterial blood sample, the sample being drawn from the same source as in a) wherein the parameters obtained for the 5 microgram/kg of FVIIa and/or 6 microgram/kg/hour of adrenaline may be obtained from the same subject being tested with the combination of a clotting factor and a sympathicomimetic agonist or a reference value / parameter obtained in advance.

By reference value is understood the values given in the above.

Preferably, a clotting factor when used in combination with a sympathicomimetic agonist and optionally also a beta blocker according to the present invention is a combination of substances capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the combination is administered such as: lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength), increasing the Lysis AUC (the area under the fibrinolysis curve AUC) and/or increasing the fibrinolysis time (LY). Preferably, the combination of a clotting factor and a sympathicomimetic agonist and optionally also a beta blocker for use according to the present invention is a combination capable of altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength). Most preferably, the combination of a clotting factor and a sympathicomimetic agonist and optionally also a beta blocker for use according to the present invention is a combination capable of altering all of the following TEG measurable parameters of the blood of a subject to which the substance is administered by lowering the R value (clotting time), lowering the K value (clot kinetics), and increasing the MA, maximal amplitude, (the maximal physical clot strength) and increasing the Angle or alpha (representing velocity of clot formation).

Also it is preferred that the hemostatic efficacy of the combination of a clotting factor and a sympathicomimetic agonist is higher / better than that of either the clotting factor or the sympathicomimetic agonist alone. The improved effect may be measured as any one or more of the following TEG measurable parameters of the blood of a subject to which the combination is administered by lowering the r value (clotting time), lowering the k value (clot kinetics), and increasing the MA, maximal amplitude, (the maximal physical clot strength) and increasing the Angle or alpha (representing velocity of clot formation).

It is understood that in any of the above embodiments, a beta blocker and or potassium may be used in combination with the clotting factor and the sympathicomimetic agonist.

Beta Blockers

A current indication for which adrenaline is used is for the treatment cardiac arrest, anaphylactic shock and other cardiac dysrhythmias resulting in diminished or absent cardiac output. The action of adrenaline is to increase peripheral resistance via α1- adrenoceptor vasoconstriction, so that blood is shunted to the body's core, and the β1- adrenoceptor response which is increased cardiac rate and output (the speed and pronouncement of heart beats) resulting in amongst others: high blood pressure. The consequence of especially the beta-1 mediated response: increased cardiac rate, cardiac output and high blood pressure, is detrimental to subjects that are bleeding, as this will increase the rate with which blood is being pumped out of the body.

Surprisingly, the inventor of the present invention has found that administration of clotting factor FVIIa in combination with low doses of adrenaline increases the hemostatic ability of the blood. If dysrhythmias, and especially tachycardia, never the less are sought prevented, an aspect of the present invention comprising the co- administration of a clotting factor and a sympathicomimetic agonist with a beta-1 blocker accommodates this. There are three known types of beta adrenergic receptors and any compound capable of blocking the action of one or more of these is of relevance to the present invention. Examples of beta blockers that may be used in combination with a clotting factor and a sympathicomimetic agonist for the prevention and/or treatment of bleeding in a subject include, but are not limited to: Acebutolol, Alprenolol, Amosulalol, Arotinolol, Atenolol, Befunolol, Betaxolol, Bevantolol, Bisoprolol, Bopindolol, Bucindolol, Bunitrolol, Bupranolol, Butaxamine, Carazolol, Carteolol, Carvedilol, Celirolol, Esmolol (Brevibloc), Indenolol, Labetalol, Landiolol, Levobetaxolol, Levobunolol, Mepindolol, Metipranolol, Metoprolol (Seloken), Nadolol, Nebivolol, Nipradilol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, Talinolol, Tertalolol, Tilisolol, and Timolol and other known or yet undiscovered chemical or biological substances or compounds where any of the above mentioned are included. Brand names of these compounds may vary from company to company and country to country; aliases of the abovementioned compounds or other beta blockers are included within the scope of the present invention.

In some embodiments, at least one beta blocker of above is used in combination with clotting factors and sympathicomimetic agonists which may include any clotting factor such as but not limited to a prothrombin complex concentrate factor and/or an activated prothrombin complex concentrate factor, and any agonist with an agonistic effect on α- adrenergic and/or β-adrenergic receptors, including any subtypes (e.g. a_r, a₂-, βi, β₂- and β₃-subtypes), of the sympathetic nervous system, such as but not limited to adrenaline, noradrenaline, dopamine, dobutamin, dobutrex, ephedrine and other known or yet undiscovered chemical or biological substances or compounds where any of the above mentioned are included.

In one embodiment of the present invention, the clotting factor comprises FVIIa, rFVIIa, rhFVIIa or a variant or analogue thereof and the sympathicomimetic agonists comprise adrenaline and/or noradrenaline and/or dobutamine and are administered in combination with at least one beta blocker such as but not limited to a non-selective agent (i.e. may bind or block the action of more than one beta adrenergic receptor), such as, but not restricted to: Alprenolol, Carteolol, Levobunolol, Mepindolol, Metipranolol, Nadolol, Oxprenolol, Penbutolol, Pindolol, Propranolol, Sotalol, and Timolol. In another embodiment of the present invention, the clotting factor comprises FVIIa or a variant or analogue thereof and the sympathicomimetic agonists comprise adrenaline and/or noradrenaline and/or dobutamine and are administered in combination with at least one beta blocker such as but not limited to β1 -selective agents such as Acebutolol, Atenolol, Betaxolol, Bisoprolol, Esmolol, Metoprolol (Seloken), Nebivolol, Amosulalol, Landiolol, and Tilisolol; or β2-Selective agents such as Butaxamine; or beta 3 selective agents.

In another embodiment, of the present invention the clotting factor comprises FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonists comprise adrenaline and/or noradrenaline and/or dobutamine and are administered in combination with at least one beta blocker with a high cardioselectivity (i.e. βi /β2 ratio) and low half life such as but not limited to Seloken, Esmolol and Landiolol.

The terms "used in combination", "administered in combination with" or "coadministered" or "composition" indicate that the drugs may be formulated together, or are kept as separate entities and may be administered simultaneously or within a predetermined interval of each other. Examples of how the clotting factors, the sympathicomimetic agonists and beta blockers of the present invention may be administered in combination with each other are given in the below.

The beta blocker of the present invention that is used in combination with a clotting factor and sympathicomimetic for the treatment of bleeding in a subject is administered in the pharmaceutically efficient dose of the particular compound. For example, Seloken may be administered in a tablet comprising 50 mg to 200 mg of Seloken and an appropriate dosage of a sympathicomimetic agonist as disclosed above. Alternatively; Seloken may be administered parenterally at doses between 1 mg and 40 mg administered in one or several dosages or intravenously at a rate of 10 to 150 ml/hour (1 mg/ml). Likewise Esmolol (tradename Brevibloc) may be administered at 0.1 to 5.0 mg/kg as an i.v. bolus injection, such as 0.5 mg/kg and/or as between 0.01 to 1 mg/kg/min i.v., such as 0.05 to 0.3 mg/kg/min as first administration or continued administration. Similarly, Landiolol may be administered intravenously at dosages between 0.01 to 5 mg/kg/min, such as 0.1 to 0.5 mg/kg/min or as bolus injections of between 1 mg to 20 mg. As is known to a person skilled in the art, the dosage of beta blocker may be increased according the necessity thereof. Potassium (K)

Adrenaline is known to have a lowering effect on serum potassium concentrations. Normal reference values for potassium in plasma is: 3,2 - 4,7 mmol/l and in serum: 3,5 - 5,0 mmol/l. Mild hypokalaemia (low concentration of potassium in the blood) is defined as a plasma potassium concentration >3.0 mmol/L and severe hypokalaemia is when the potassium concentration is < 3.0 mmol/L. Epinephrine in the doses to be administered for the prevention and/or treatment of bleeding in a subject lowers the potassium concentration to approximately 3.3 mmol/l. and is thus not expected to cause hypokalaemia. Nevertheless, an embodiment of the present invention comprises administration of potassium at a concentration of or in an amount corresponding to between 1 mmol/L to 30 mmol/L, or 1.5 mmol/L to 25 mmol/L, or 2 mmol/L to 20 mmol/L, or 2.5 mmol/L to 15 mmol/L, or 3 mmol/L to 10 mmol/L, or 4 mmol/L to 5 mmol/L. Preferably, potassium is comprised in an amount that counter the effect of the sympathicomimetic compound and thus retains the plasma potassium concentration within the normal range. The "normal range" may be the pharmaceutically / medically accepted range of potassium concentrations found in human beings or may be individualized so the plasma concentration of potassium measured in the individual prior to commencement of treatment may be kept at the measured level.

An embodiment of the present invention relates to the administration of a a clotting factor in combination with a sympathicomimetic agonist in a formulation comprising potassium at a concentration betweeni mmol/L and 30 mmol/L for the prevention and/or treatment of bleeding in a subject.

Thus in one aspect, the treatment of bleeding in a subject comprises the administration of at least one clotting factor comprising a prothrombin complex concentrate factor and/or an activated prothrombin complex concentrate factor and at least one of the following sympathicomimetic agonists: adrenaline, noradrenaline, dopamine, dobutamin, dobutrex, and ephedrine in combination with potassium at a concentration betweeni mmol/L and 30 mmol/L. Most preferably, FVIIa or a variant or analogue thereof, and adrenaline and/or noradrenaline are administered in combination with potassium at a concentration of betweeni mmol/L and 30 mmol/L. Likewise, another embodiment of the present invention relates to the administration of a clotting factor and a sympathicomimetic agonist in combination with a beta blocker in a formulation further comprising potassium at a concentration between 1 mmol/L and 30 mmol/L for the prevention and/or treatment of bleeding in a subject.

Thus in one aspect, the treatment of bleeding in a subject comprises the administration of at least one clotting factor comprising a prothrombin complex concentrate factor and/or an activated prothrombin complex concentrate factor and at least one of the following sympathicomimetic agonists: adrenaline, noradrenaline, dopamine, dobutamin, dobutrex, and ephedrine in combination with a beta blocker, the blocker preferably being a beta 1 receptor specific blocker and further being administered in combination with potassium at a concentration betweeni mmol/L and 30 mmol/L. Most preferably, FVIIa, adrenaline and/or noradreline are administered in combination potassium at a concentration of betweeni mmol/L and 30 mmol/L.

The administration of potassium may follow that of the administration of the clotting factor and the sympathicomimetic agonist or be independent hereof. For instance, the administration of potassium may precisely follow the administration of e.g. adrenaline or FVIIa such that the administration of potassium starts and/or stops with the administration of adrenaline or FVIIa.

For example: if the administration of adrenaline lowers the plasma potassium concentration of the individual compared to normal levels or compared to the level measured in the individual prior to adrenaline administration, potassium may be administered to counter this lowering bringing the concentration of plasma potassium back to normal. Preferably, the administration of potassium stops at the same time as the administration of the clotting factor and/or the sympathicomimetic agonist and/or beta blocker.

Administration

Administration of the clotting factors and sympathicomimetic agonists is to be given to a subject resulting in a systemic concentration of the clotting factors and sympathicomimetic agonists. Methods of administration include enteral, such as oral, sublingual, gastric, intraalveolar or rectal and/or parenterally, that is by intravenous, intramuscular, subcutaneous, intranasal, intrapulmonary, intrarectal, intravaginal, intraosseous or intraperitoneal administration. The subcutaneous and intravenous forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. The compounds may also be administered by inhalation that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.

The compounds according to the invention may be administered with at least one other compound. The compounds may be administered simultaneously, either as separate formulations or combined in a unit dosage form, or administered sequentially.

As used herein, "dose" shall mean any concentration of the clotting factors and sympathicomimetic agonists administered producing a pro-hemostatic effect on the hemostatic system. A dose sufficient to produce the desired effect in relation to the conditions for which it is administered, in particular an amount of a clotting factor and sympathicomimetic agonists that is effective to stop, reduce or prevent the unwanted bleeding shall be described as the "effective dose", "therapeutically effective dose" or "effective amount". Normally the dose should be capable of preventing or lessening the severity or spread of the condition or indication being treated. The exact dose will depend on the circumstances, such as the condition being treated, the administration schedule, whether the clotting factor and sympathicomimetic agonists is administered alone or in conjunction with another therapeutic agent or another clotting factor or sympathicomimetic agonists, the plasma half-life of the clotting factor and the sympathicomimetic agonists and the general health of the subject.

As will be understood by the person skilled in the art, amounts effective for this purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. The dose is preferably given by the parenteral administration route, notably the intravenous, intramuscular, intraosseous and/or the subcutaneous, sublingual, trans-mucosal, intrapulmonal and intra-alveolar route. The dosages given in the following is contemplated to be in the same order of magnitude irrespective of the parenteral administration route.

The normal dose of FVIIa given is usually in the range of 25-200 microgram/kg. Surprisingly, the inventor has discovered that low doses of up to 20 microgram/kg of the clotting factor FVIIa is most effective. The dose given should preferably induce a appropriate systemic concentration of FVIIa in the range of 0.1 to 10 microgram/kg, such as 0.2 to 8 microgram/kg, for example 0.3 to 7 microgram/kg, such 0.4 to 6 microgram/kg, for example 0.5 to 5 microgram/kg, such as 0.7 to 4 microgram/kg, for example 0.8 to 4 microgram/kg, such as 0.9 to 3 microgram/kg, such as around 1 microgram/kg.

Thus, for the clotting factor FVIIa the dose administered will for enteral and/or parenteral, notably oral, intravenous, intramuscular and/or subcutaneous routes, single or repeated bolus dose(s) be in the range of from 1 microgram/kg to 20 microgram/kg, 1.5 microgram/kg to 20 microgram/kg, such as 2 microgram/kg to 20 microgram/kg, such as 3 microgram/kg to 20 microgram/kg, such as 4 microgram/kg to 20 microgram/kg, such as 5 microgram/kg to 20 microgram/kg, or any interval therein between. Alternatively, for the clotting factor FVIIa, the dose for parenteral administration, notably intravenous infusion, will be in the range of from 0,1 microgram/kg to 20 microgram/kg, or 0,5 microgram/kg to 20 microgram/kg, or 1 microgram/kg to 20 microgram/kg, or any interval therein between.

In an embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 1 microgram/kg.

In a specific embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous routes in a single or repeated bolus dose of about 5 microgram/kg.

In a further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 10 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 15 microgram/kg. In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 16, 17, 18, or 19 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 20 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 21 , 22, 23, or 24 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 25 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 30 microgram/kg.

In a still further embodiment the clotting factor FVIIa or rFVIIa, the dose administered will for intravenous, intramuscular and/or subcutaneous single or repeated bolus dose be about 40 microgram/kg.

The bolus injection may be given once, twice or several times, for instance, in keeping with the dosage administered the bolus injection may be given every 5 min (minutes), such as every 10 min, such as every 15 min, such as every 20 min, such as every 25 min, such as every 30 min, such as every 35 min, such as every 40 min, such as every 45 min, such as every 50 min, such as every 55 min, such as every 60 min such as every 70 min, such as every 80 min, such as every 90 min, such as every 100 min, such as every 110 min such as every 120 min or more. For example, the bolus dosage may be administered in the appropriate intervals from the time of trauma to the subject and until a treatment facility such as a hospital or other is reached. The bolus injection may be followed by a maintenance dose. Such dosages are described in the following; however, in specific embodiments, the following dosages may also be used without any bolus injection. For the clotting factor FVIIa, the dose for parenteral administration, notably intravenous or intraosseous infusion, will be in the range of from 0.1 microgram/kg/hour to 30 microgram/kg/hour, such as 0.5 microgram/kg/hour to 29 microgram/kg/hour, such as 0.7 microgram/kg/hour to 28 microgram/kg/hour, such as 0.8 microgram/kg/hour to 27 microgram/kg/hour, such as 0.9 microgram/kg/hour to 26 microgram/kg/hour, such as 1 microgram/kg/hour to 25 microgram/kg/hour or any interval therein between. Alternatively, the interval may be between 1 microgram/kg/hour to 20 microgram/kg/hour, 1.5 microgram/kg/hour to 19.5 microgram/kg/hour, such as 2 microgram/kg/hour to 19 microgram/kg/hour, such as 2.5 microgram/kg/hour to 18.5 microgram/kg/hour, such as 3 microgram/kg/hour to 18 microgram/kg/hour, such as 3.5 microgram/kg/hour to 17.5 microgram/kg/hour, such as 4 microgram/kg/hour to 17 microgram/kg/hour, such as 4.5 microgram/kg/hour to 16.5 microgram/kg/hour, such as 5 microgram/kg/hour to 16 microgram/kg/hour, such as 5.5 microgram/kg/hour to 15.5 microgram/kg/hour, such as 6 microgram/kg/hour to 15 microgram/kg/hour, such as 6.5 microgram/kg/hour to 14.5 microgram/kg/hour, such as 7 microgram/kg/hour to 14 microgram/kg/hour, such as 7.5 microgram/kg/hour to 13.5 microgram/kg/hour, such as 8 microgram/kg/hour to 13 microgram/kg/hour, such as 8.5 microgram/kg/hour to 12.5 microgram/kg/hour, such as 9 microgram/kg/hour to 12 microgram/kg/hour or any interval therein between. Alternatively, for the clotting factor Vila, the dose for parenteral administration, notably intravenous or intraosseous infusion, will be in the range of from 1 microgram/kg/hour to 10 microgram/kg/hour, or 1.5 microgram/kg/hour to 9.5 microgram/kg/hour, or 2 microgram/kg/hour to 9 microgram/kg/hour, or 2.5 to 8.5 microgram/kg/hour, or 2.5 microgram/kg/hour to 8.5 microgram/kg/hour, or 3 microgram/kg/hour to 8 microgram/kg/hour, or 3.5 microgram/kg/hour to 7.5 microgram/kg/hour, or 4 microgram/kg/hour to 7 microgram/kg/hour or any interval therein between.

In an embodiment the intravenous infusion of the clotting factor FVIIa will be about 0,1 microgram/kg/hour.

In an embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 1 microgram/kg/hour. In a specific embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 2 microgram/kg/hour.

In a further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 3 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 4 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 6 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 7 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 8 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 9 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 10 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 1 1 , 12, 13 or 14 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 15 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 16, 17, 18 or 19 microgram/kg/hour. In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 20 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 21 , 22, 23 or 24 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the clotting factor FVIIa or rFVIIa will be about 25 microgram/kg/hour.

The infusion may be of any duration necessary such as from 1 minute (min) to several hours if required. The dosage can, due to the rapid turnover of FVIIa or rFVIIa and similar compounds be administered continuously without risk of accumulation. Thus it is an object of the invention to infuse a subject for the prophylaxis or treatment of bleeding for more than 1 min such as 5 min, such as 10 min, such as 15 min, such as 20 min, such as 25 min, such as 30 min, such as 35 min, such as 40 min, such as 45 min, such as 50 min, such as 55 min, such as 60 min, such as 65 min, such as 70 min, such as 75 min, such as 80 min, such as 85 min, such as 90 min, such as 95 min, such as 100 min, such as 105 min, such as 110 min, such as 120 min, such as 130 min, such as 140 min, such as 150 min, such as 160 min, such as 170 min, such as 180 min, such as 190 min, such as 200 min, such as 210 min, such as 220 min, such as 230 min, such as 240 min or more.

For the sympathicomimetic agonists adrenaline and noradrenaline the dose administered should have an effect corresponding to in the range of 1 to 30 minutes of intravenous infusion, such as 2 minutes to 27 minutes, for example 5 minutes to 25 minutes, such as 7 minutes to 23 minutes, for example 10 minutes to 20 minutes such as 15 minutes of intravenous infusion of in the range of from 0.1 microgram/kg/hour to about 50 microgram/kg/hour in fully awake, non-anesthetized patients, such as in the range of from 1 microgram/kg/hour to 10 microgram/kg/hour, or 1.5 microgram/kg/hour to 9.5 microgram/kg/hour, or 2 microgram/kg/hour to 9 microgram/kg/hour, or 2.5 microgram/kg/hour to 8.5 microgram/kg/hour, or 3 microgram/kg/hour to 8 microgram/kg/hour, or 3.5 microgram/kg/hour to 7.5 microgram/kg/hour, or 4 microgram/kg/hour to 7 microgram/kg/hour or any interval therein between, such as around 6 microgram/kg/hour. In a most preferred embodiment the dose of the sympathicomimetic agonists adrenaline or noradrenaline administered to individuals being treated for trauma should correspond to the effect of administering to fully awake, non-anesthetized patients by intravenous infusion 6 microgram/kg/hour of the sympathicomimetic agonists adrenaline for 15 minutes.

For anesthetized patients the dose of sympathicomimetic agonists adrenaline and noradrenaline administered should have an effect corresponding to in the range of 1 to 30 minutes of intravenous infusion, such as 2 minutes to 27 minutes, for example 5 minutes to 25 minutes, such as 7 minutes to 23 minutes, for example 10 minutes to 20 minutes such as 15 minutes of intravenous infusion of in the range of from 0.1 microgram/kg/hour to about 50 microgram/kg/hour, such as in the range of from 0.5 microgram/kg/hour to 10 microgram/kg/hour, or 1.0 microgram/kg/hour to 9.5 microgram/kg/hour, or 1.5 microgram/kg/hour to 9 microgram/kg/hour, or 2.0 microgram/kg/hour to 8.5 microgram/kg/hour, or 2.5 microgram/kg/hour to 8 microgram/kg/hour, such as around 3 - 3.5 microgram/kg/hour. In a most preferred embodiment, the dose of the sympathicomimetic agonists adrenaline or noradrenaline administered to individuals undergoing elective surgery (that is any surgery with a risk of bleeding episodes) should correspond to the effect of administering to anesthetized patients by intravenous infusion 3 - 3.5 microgram/kg/hour for 15 minutes of the sympathicomimetic agonists adrenaline.

Thus, for the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for enteral and/or parenteral, notably oral, intravenous, intraosseous, intramuscular and/or subcutaneous routes, single or repeated bolus dose(s) be in the range of from 0.1 μg/kg to about 50 μg/kg, such as, e.g., from about 0.5 μg/kg to about 50 μg/kg, from about 1 microgram/kg to 50 microgram/kg, such as e.g. 2 microgram/kg to 20 microgram/kg, 2.5 microgram/kg to 15 microgram/kg, 3 microgram/kg to 14 microgram/kg or 3.5 microgram/kg to 13 microgram/kg, or 4 microgram/kg to 12 microgram/kg, or 4.5 microgram/kg to 11 microgram/kg, or 5 microgram/kg to 10 microgram/kg, or 5.5 microgram/kg to 9 microgram/kg, or 6 microgram/kg to 8 microgram/kg. Alternatively the parenteral, notably intravenous, intramuscular, intraosseous, and/or subcutaneous routes, single or repeated bolus dose(s) are in the range of from 0.01 microgram/kg to 100 microgram/kg, such as 0.02 microgram/kg to 90 microgram/kg, such as 0.03 microgram/kg to 80 microgram/kg, such as 0.04 microgram/kg to 70 microgram/kg, such as 0.05 microgram/kg to 60 microgram/kg, such as 0.06 microgram/kg to 50 microgram/kg, such as 0.07 microgram/kg to 40 microgram/kg, such as 0.08 microgram/kg to 30 microgram/kg, such as 0.09 microgram/kg to 27.5 microgram/kg, such as 0.1 microgram/kg to 25 microgram/kg, such as 0.2 microgram/kg to 24 microgram/kg, such as 0.2 microgram/kg to 23 microgram/kg such as 0.3 microgram/kg to 22 microgram/kg, such as 0.4 microgram/kg to 21 microgram/kg, such as 0.5 microgram/kg to 20 microgram/kg, such as 0.6 microgram/kg to 19 microgram/kg, such as 0.7 microgram/kg to 18 microgram/kg, such as 0.8 microgram/kg to 17 microgram/kg, such as 0.9 microgram/kg to 16 microgram/kg, such as 1 microgram/kg to 15 microgram/kg. Alternatively, the interval may be between 1 microgram/kg to 20 microgram/kg, 1.5 microgram/kg to 19.5 microgram/kg, such as 2 microgram/kg to 19 microgram/kg, such as 2.5 microgram/kg to 18.5 microgram/kg, such as 3 microgram/kg to 18 microgram/kg, such as 3.5 microgram/kg to 17.5 microgram/kg, such as 4 microgram/kg to 17 microgram/kg, such as 4.5 microgram/kg to 16.5 microgram/kg, such as 5 microgram/kg to 16 microgram/kg, such as 5.5 microgram/kg to 15.5 microgram/kg, such as 6 microgram/kg to 15 microgram/kg, such as 6.5 microgram/kg to 14.5 microgram/kg, such as 7 microgram/kg to 14 microgram/kg, such as 7.5 microgram/kg to 13.5 microgram/kg, such as 8 microgram/kg to 13 microgram/kg, such as 8.5 microgram/kg to 12.5 microgram/kg, such as 9 microgram/kg to 12 microgram/kg or any interval therein between. Alternatively, for the sympathicomimetic agonists adrenaline and noradrenaline, the dose for parenteral administration, notably intravenous infusion, will be in the range of from 1 microgram/kg to 10 microgram/kg, or 1.5 microgram/kg to 9.5 microgram/kg, or 2 microgram/kg to 9 microgram/kg, or 2.5 to 8.5 microgram/kg, or 2.5 microgram/kg to 8.5 microgram/kg, or 3 microgram/kg to 8 microgram/kg, or 3.5 microgram/kg to 7.5 microgram/kg, or 4 microgram/kg to 7 microgram/kg or any interval therein between.

In an embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 1 microgram/kg.

In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 2 microgram/kg. In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 2.5 microgram/kg.

In a further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 3 microgram/kg.

In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 3.5 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 4 microgram/kg.

In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 4.5 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 5 microgram/kg. In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 5.5 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 6 microgram/kg. In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 6.5 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 7 microgram/kg.

In a specific embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous routes in a single or repeated bolus dose of about 7.5 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 8 microgram/kg.

In a still further embodiment the sympathicomimetic agonists adrenaline and noradrenaline the dose administered will for intravenous, intramuscular, intraosseous, and/or subcutaneous single or repeated bolus dose is about 9 microgram/kg.

The bolus injection may be given once, twice or several times, for instance, in keeping with the dosage administered the bolus injection may be given every 5 min (minutes), such as every 10 min, such as every 15 min, such as every 20 min, such as every 25 min, such as every 30 min, such as every 35 min, such as every 40 min, such as every 45 min, such as every 50 min, such as every 55 min, such as every 60 min such as every 70 min, such as every 80 min, such as every 90 min, such as every 100 min, such as every 110 min such as every 120 min or more. For example, the bolus dosage may be administered in the appropriate intervals from the time of trauma to the subject and until a treatment facility such as a hospital or other is reached.

The bolus injection may be followed by a maintenance dose. Such dosages are described in the following; however, in specific embodiments, the following dosages may also be used without any bolus injection. For the sympathicomimetic agonists adrenaline and noradrenaline, the dose for parenteral administration, notably intravenous infusion, will be in the range of from 0.01 microgram/kg/hour to 100 microgram/kg/hour, such as 0.02 microgram/kg/hour to 90 microgram/kg/hour, such as 0.03 microgram/kg/hour to 80 microgram/kg/hour, such as 0.04 microgram/kg/hour to 70 microgram/kg/hour, such as 0.05 microgram/kg/hour to 60 microgram/kg/hour, such as 0.06 microgram/kg/hour to 50 microgram/kg/hour, such as 0.07 microgram/kg/hour to 40 microgram/kg/hour, such as 0.08 microgram/kg/hour to 30 microgram/kg/hour, such as 0.09 microgram/kg/hour to 27.5 microgram/kg/hour, such as 0.1 microgram/kg/hour to 25 microgram/kg/hour, such as 0.2 microgram/kg/hour to 24 microgram/kg/hour, such as 0.2 microgram/kg/hour to 23 microgram/kg/hour such as 0.3 microgram/kg/hour to 22 microgram/kg/hour, such as 0.4 microgram/kg/hour to 21 microgram/kg/hour, such as 0.5 microgram/kg/hour to 20 microgram/kg/hour, such as 0.6 microgram/kg/hour to 19 microgram/kg/hour, such as 0.7 microgram/kg/hour to 18 microgram/kg/hour, such as 0.8 microgram/kg/hour to 17 microgram/kg/hour, such as 0.9 microgram/kg/hour to 16 microgram/kg/hour, such as 1 microgram/kg/hour to 15 microgram/kg/hour. Alternatively, the interval may be between 1 microgram/kg/hour to 20 microgram/kg/hour, 1.5 microgram/kg/hour to 19.5 microgram/kg/hour, such as 2 microgram/kg/hour to 19 microgram/kg/hour, such as 2.5 microgram/kg/hour to 18.5 microgram/kg/hour, such as 3 microgram/kg/hour to 18 microgram/kg/hour, such as 3.5 microgram/kg/hour to 17.5 microgram/kg/hour, such as 4 microgram/kg/hour to 17 microgram/kg/hour, such as 4.5 microgram/kg/hour to 16.5 microgram/kg/hour, such as 5 microgram/kg/hour to 16 microgram/kg/hour, such as 5.5 microgram/kg/hour to 15.5 microgram/kg/hour, such as 6 microgram/kg/hour to 15 microgram/kg/hour, such as 6.5 microgram/kg/hour to 14.5 microgram/kg/hour, such as 7 microgram/kg/hour to 14 microgram/kg/hour, such as 7.5 microgram/kg/hour to 13.5 microgram/kg/hour, such as 8 microgram/kg/hour to 13 microgram/kg/hour, such as 8.5 microgram/kg/hour to 12.5 microgram/kg/hour, such as 9 microgram/kg/hour to 12 microgram/kg/hour or any interval therein between. Alternatively, for the sympathicomimetic agonists adrenaline and noradrenaline, the dose for parenteral administration, notably intravenous infusion, will be in the range of from 1 microgram/kg/hour to 10 microgram/kg/hour, or 1.5 microgram/kg/hour to 9.5 microgram/kg/hour, or 2 microgram/kg/hour to 9 microgram/kg/hour, or 2.5 to 8.5 microgram/kg/hour, or 2.5 microgram/kg/hour to 8.5 microgram/kg/hour, or 3 microgram/kg/hour to 8 microgram/kg/hour, or 3.5 microgram/kg/hour to 7.5 microgram/kg/hour, or 4 microgram/kg/hour to 7 microgram/kg/hour or any interval therein between.

In an embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 1 microgram/kg/hour.

In a specific embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 2 microgram/kg/hour.

In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 3 microgram/kg/hour.

In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 3.5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 4 microgram/kg/hour.

In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 4.5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 5 microgram/kg/hour.

In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 5.5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 6 microgram/kg/hour.

In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 6.5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 7 microgram/kg/hour. In a further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 7.5 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 8 microgram/kg/hour.

In a still further embodiment the intravenous infusion of the sympathicomimetic agonists adrenaline and noradrenaline will be about 9 microgram/kg/hour.

The infusion may be of any duration necessary such as from 1 minute (min) to several hours if required. The dosage can, due to the rapid turnover of adrenaline and similar compounds be administered continuously without risk of accumulation. Thus it is an object of the invention to infuse a subject for the prophylaxis or treatment of bleeding for more than 1 min such as 5 min, such as 10 min, such as 15 min, such as 20 min, such as 25 min, such as 30 min, such as 35 min, such as 40 min, such as 45 min, such as 50 min, such as 55 min, such as 60 min, such as 65 min, such as 70 min, such as 75 min, such as 80 min, such as 85 min, such as 90 min, such as 95 min, such as 100 min, such as 105 min, such as 110 min, such as 120 min, such as 130 min, such as 140 min, such as 150 min, such as 160 min, such as 170 min, such as 180 min, such as 190 min, such as 200 min, such as 210 min, such as 220 min, such as 230 min, such as 240 min or more.

Any sympathicomimetic able of inducing an activation of the hemostatic system equal to the above mentioned dose of adrenaline and noradrenaline i.e. dopamine at a dose of 10-100 x higher (30-300 microgram/kg/hour) than adrenaline and noradrenaline and dobutamin at a dose of 10-100 x higher in (30-300 microgram/kg/hour) adrenaline and noradrenaline. Based on this information it is contemplated that a person skilled in the art can choose a proper dosage.

Single or multiple administrations of the compositions and combination of clotting factors, sympathicomimetic agonists, beta blockers and/or potassium can be carried out with dose levels and patterns being selected by the treating physician. In one embodiment clotting factor is administered as a bolus dose which is followed by a continuous dose of sympathicomimetic agonists.

The clotting factor, sympathicomimetic agonist and the beta blocker may be co- administered optionally in combination with potassium as soon as the subject is asleep and the administration may be stopped after last suture.

The combination of clotting factor and sympathicomimetic agonist and beta blocker acts instantaneously with regard to development of the pro-hemostatic response, and development of tachycardia/tachyarrhythmia is prevented by an initial loading dose of the beta blocker starting prior to the administration of the sympathicomimetic agonist followed by a continuous infusion. Thus, due to i.e. differences in turn over rate of the sympathicomimetic agonist and the beta blocker (the beta blocker in the following example having the longer turn over rate) and optionally the potassium may be administered such that the blocker is administered for a number of minutes (between 1 and 5 minutes) prior to administration of the sympathicomimetic agonist and likewise towards the end of the treatment, the administration of the blocker is discontinued first, for example 5 to 20 minutes before stopping the administration of the sympathicomimetic agonist. The potassium may be co-administered with the sympathicomimetic agonist.

Likewise, the pro-hemostatic effect of the sympathicomimetic agonist / beta blocker is abated within a well defined time after discontinuation of the infusion and the administration of the blocker will therefore be adjusted so the blockage of the cardiac beta receptors is reversed when the haemodynamic effect of the sympathicomimetic agonist is abated. It will therefore be possible to discontinue the infusion of the sympathicomimetic agonist / beta blocker, well before the surgical procedure is finalized and bleeding has been controlled and the pro-hemostatic effect of the product will not be measurable by TEG MA 30-60 min postoperatively.

In prophylactic applications, compositions containing the clotting factor and the sympathicomimetic agonist of the invention are administered to a subject susceptible to or otherwise at risk of a disease state or injury to enhance the subject's own hemostatic capability. Such an amount is defined to be a "prophylactically effective dose." In prophylactic applications, the precise amounts once again depend on the subject's state of health and weight, and it is anticipated that the dose generally will be as specified above.

The beta blockers of the present invention may be administered in the dosages recommended by the manufacturers or as are known to be efficient to those skilled in the art, i.e. medical practitioners.

Pharmaceutical compositions of the invention and its use

The present invention also relates to a pharmaceutical composition comprising one or more clotting factors and and/or one or more sympathicomimetic agonists and optionally potassium and one or more pharmaceutically acceptable carriers or excipients. Such pharmaceutically acceptable carriers or excipients as well as suitable pharmaceutical formulation methods are well known in the art (see for example Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa. In a preferred embodiment the sympathicomimetic agonist and the clotting factor are prepared in a parenteral composition. Such methods for preparing parenterally administrable compositions will also be known or apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Company, Easton, Pa (1990). As used herein, the term "pharmaceutical acceptable" means a carriers or excipients that does not cause any untoward effects in subjects to whom it is administered.

Pharmaceutically acceptable salts Pharmaceutically acceptable salts of the instant compounds, where they can be prepared, are also intended to be covered by this invention. These salts will be ones which are acceptable in their application to a pharmaceutical use. By that it is meant that the salt will retain the biological activity of the parent compound and the salt will not have untoward or deleterious effects in its application and use in treating diseases.

Pharmaceutically acceptable salts are prepared in a standard manner. If the parent compound is a base it is treated with an excess of an organic or inorganic acid in a suitable solvent. If the parent compound is an acid, it is treated with an inorganic or organic base in a suitable solvent. The compounds of the invention may be administered in the form of an alkali metal or earth alkali metal salt thereof, concurrently, simultaneously, or together with a pharmaceutically acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parenteral (including subcutaneous) route, in an effective amount.

Examples of pharmaceutically acceptable acid addition salts for use in the present inventive pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, for example.

The compositions for parenteral administration comprise the clotting factor of the invention and/or the sympathicomimetic agonist of the invention in combination with, preferably dissolved in, a pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be used, such as water, buffered water, lactated Ringer's solution, saline, e.g. such as 0.7%, 0.8%, 0.9% or 1%, glycine such as 0.2%, 0.3%, 0.4% or 0.5% and the like. Normally, it is aimed that the composition has an osmotic pressure corresponding to a 0.9% w/w sodium chloride solution in water. Moreover, as known by a person skilled in the art, dependent on the specific administration route, pH may be adjusted within suitable ranges centered around pH 7.4. The compositions may be sterilized by conventional, well-known sterilization techniques. The resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.

The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or non-aqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

Oils useful in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils useful in such formulations include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides; (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example, alkyl-. beta. -aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

The parenteral formulations typically will contain from about 0.5 to about 25% by weight of the active ingredient in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5 to about 15% by weight. Suitable surfactants include polyethylene sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The clotting factor and/or sympathicomimetic agonist and/or beta blocker and/or potassium may be formulated so it can be stored at room temperature in preformed bags or syringes containing the solution with the clotting factor and/or sympathicomimetic agonist and/or potassium. The bag may be compartmentalized enabling an initial loading dose of the beta blocker before infusion of the sympathicomimetic agonist and/or clotting factor and/or potassium commence. Likewise, the syringe may be for single or dual injections and optionally allowing premixing of sympathicomimetic agonist, clotting factor and optionally beta blocker. The concentration of the clotting factor, sympathicomimetic agonist and optionally beta blocker is predefined enabling immediate dosing based on the patients weight regardless of age and gender. The preformed bag may be a 1 liter or a 500 ml or any other conventionally sized bag formulated to tolerate light and be stable at room temperature. The syringe may be a 50 ml syringe, or a syringe of any conventional size such as between 10 ml and 100 ml.

The pharmaceutical composition may also be formulated in other forms e.g. as a gel, liquid, or as compressed solid. The preferred form will depend upon the particular indication being treated and will be apparent to one skilled in the art.

The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, stabilizing agents, preservatives, non-ionic surfactants or detergents, antioxidants, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.

The sympathicomimetic agonists may also be in a salt form thereof. Suitable salts include, but are not limited to, salts with alkali metals or earth metals, such as sodium, potassium, calcium and magnesium as well as e.g. zinc salts. These salts or complexes may be present as a crystalline and/or amorphous structure.

Administration of the clotting factors and the sympathicomimetic agonists for the treatment of bleeding episodes may either be the sole treatment or in any combination with other therapeutic agents such as red blood cells, and /or plasma and /or platelets and/or other procoagulants such as any of the coagulation factors alone or in combination and/or antifibrinolytics such as aprotinin, tranexamic acid amnio caproic acid, and or vasocontrictors.

Administration of the clotting factors and the sympathicomimetic agonists for the treatment of bleeding episodes may also be in combination with vitamin K.

These agents may be incorporated as part of the same pharmaceutical composition or may be administered separately from the clotting factor and sympathicomimetic agonists, either concurrently or in accordance with another treatment schedule.

The clotting factors and sympathicomimetic agonists are primarily intended for parenteral administration for prophylactic and/or therapeutic treatment. Preferably, the clotting factors and the sympathicomimetic agonists are administered parenterally, i.e., intravenously, subcutaneously, intraosseously or intramuscularly, sublingual, mucosaaplication, intrapulmonary and it may be administered by continuous or pulsatile infusion. The clotting factors and sympathcomimetic agonists can be administered separately or in any combination both for therapeutic or prophylactic use.

In another aspect of the present invention, it has been found that clot strength is better correlated with postoperative coagulopathic bleeding in subjects than conventional coagulation analysis including prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count and fibrinogen levels undergoing cardiac surgery (Welsby et al. 2006). The clot strength can be approached by use of e.g. thrombelastography (TEG), as will be explained in details in the examples herein. Adhering to a transfusion algorithm aiming at a normal TEG clot strength reduces bleeding and postoperative transfusion requirements in cardiac surgery, liver transplantation and in critically ill patients as shown by Shore-Lesserson et al. (1999), Kang (1995) and Johansson et al. (2007).

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms. The pharmaceutical compositions and dosage forms may comprise the compounds of the invention or its pharmaceutically acceptable salt or a crystal form thereof as the active component. The pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, wetting agents, tablet disintegrating agents, or an encapsulating material.

Preferably, the composition will be about 0.5% to 75% by weight of a compound or compounds of the invention, with the remainder consisting of suitable pharmaceutical excipients. For oral administration, such excipients include pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like.

In powders, the carrier is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably containing from one to about seventy percent of the active compound(s). Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound(s) with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be as solid forms suitable for oral / sublingual administration.

Examples of a typical tablet

A typical tablet which may be prepared by conventional tabletting techniques may contain:

Core:

Sympathicomimetic agonist and/or clotting factor (as free compound(s) or salt(s)thereof)

Colloidal silicon dioxide (Aerosil) Cellulose, microcryst. (Avicel) Modified cellulose gum (Ac-Di-SoI) Magnesium stearate

Coating:

HPMC approx. 9 mg

^*Mywacett 9-40 T approx. 0.9 mg

^*Acylated monoglyceride used as plasticizer for film coating.

Optionally a beta blocker and/or potassium may also be included in the formulation.

Drops according to the present invention may comprise sterile or non-sterile aqueous or oil solutions or suspensions, and may be prepared by dissolving the active ingredient in a suitable aqueous solution, optionally including a bactericidal and/or fungicidal agent and/or any other suitable preservative, and optionally including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 degree C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container aseptically. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01 %). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Other forms suitable for oral administration include liquid form preparations including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions, toothpaste, gel dentrifrice, chewing gum, or solid form preparations which are intended to be converted shortly before use to liquid form preparations. Emulsions may be prepared in solutions in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents. Solid form preparations include solutions, suspensions, and emulsions, and may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The compounds of the present invention may also be formulated for sublingual administration. Sublingual administration is particularly suitable for administration to patients with swallowing difficulties, for paediatric use or trauma patients. Patients may have difficulty in swallowing because of a throat disorder or injury and the presently claimed formulation is particularly beneficial in these cases. Patients may also not have a large quantity of saliva so that a larger tablet may not be completely and rapidly dissolved if at all. Passage of an undissolved dosage form from the mouth into the throat is thus undesirable and is avoided using the formulations of the invention. It is therefore to minimise the size of the dosage form and dosage forms in accordance with this invention preferably have a minimum size, eg 6 mm diameter and corresponding weight whilst maintaining the dosage. Preferably the total tablet weight does not exceed 100 mg, and more preferably it is less than 70 mg. Rapid dissolution of the dosage form which is necessary to facilitate sublingual absorption may be achieved by selection of an appropriate method of tablet manufacture. Use of direct compression or dry granulation has been found to be less suitable than wet granulation, due to the high bulk density and electrostatic properties of morphine salts, for example morphine sulphate, and excipients. According to another aspect of the present invention, a method of manufacture of a pharmaceutical solid dosage form of a clotting factor and a sympathicomimetic agonist and optionally a beta blocker and/or potassium comprises the steps of:

mixing clotting factor and a sympathicomimetic agonist and optionally a beta blocker and/or potassium with one or more excipients selected from saccharides, disintegrants and binders;

wet granulating the mixture;

milling, drying and sieving the resultant granules;

adding a lubricant; and

compressing the resultant granulate into tablets.

In a preferred method all of the saccharide or mixture saccharides is granulated together with the compounds of the present invention and a proportion of the disintegrant, the dried, sieved granulate being combined with the remainder of the disintegrant and lubricant and compressed into tablets. This method provides better homogeneity of granulate than if a proportion of the saccharide is added after granulation.

Granulation may be carried out using water or an aqueous solvent mixture. Preferably, the average particle size is not more than 0.3 mm to facilitate tableting into a stable formulation. The mesh size used in the granulation step should preferably be less than 0.70 mm in order to obtain the advantageous particle size distribution.

Tablets of the present invention preferably comprise compacted granulates together with an extra-granular disintegrant and a minimal quantity of an extra-granular lubricant.

Further, a minimum number of excipients is preferred in order to enhance the sublingual absorption. Thus a preferred formulation includes only the salt of compounds of the present invention, the filler (preferably mannitol, lactose, xylitol and mixtures thereof), the binder (preferably gelatin), and the disintegrant.

The compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatin or blister packs from which the powder may be administered by means of an inhaler.

When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The pharmaceutical carrier Illustrative solid carriers include lactose, terra alba, sucrose, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and the like. A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions, and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatine, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Illustrative liquid carriers include syrup, peanut oil, olive oil, water, etc. Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carders are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal, intraosseous or subcutaneous injection. Sterile solutions can also be administered intravenously. The compound can also be administered orally either in liquid or solid composition form.

Several scenarios can be envisaged where administration of a clotting factor and a sympathicomimetic agonist and/or a beta blocker and/or potassium would be of benefit to a bleeding subject. One is in the hospital / clinic or other similarly well supervised conditions where the subject either will be undergoing planned surgery or is admitted in a state that requires surgery. In such instances an embodiment of the present invention comprising a clotting factor and a sympathicomimetic agonist and/or a beta blocker and/or potassium in a pre-prepared and ready to use solution such as in an infusion bag or pre-prepared syringe will be preferable. The pre-prepared solution may then be administered prior to, during or after surgery. A specially preferred embodiment of this aspect of the present invention comprises a pre-prepared formulation of a clotting factor, a sympathicomimetic agonist, and a beta blocker and/or potassium that may be stored at ambient temperature, i.e. room temperature, and which also is unaltered (i.e. the compounds do not degrade / breakdown become metabolized or otherwise loose their activity) if exposed to light. Furthermore it is preferred if the formulation is such that it may be administered in the correct dosage immediately,

Another scenario is following a situation of emergency such as a traffic accident, military exercise or warfare where the bleeding subject will benefit from immediate staunching of the bleeding. In this scenario, a pre-prepared formulation may be of a clotting agent a sympathicomimetic agonist and/or a beta blocker and/or potassium, preferably just a clotting factor and a sympathicomimetic agonist in a form that allows immediate administration i.e. in a pre-prepared syringe (for i.e. intra muscular, intravenous or subcutaneous administration) or tablet or other mucosal application form. This formulation may be administered to the subject at the scene, in an ambulance or helicopter, ie. in a pre-hospital setting.

An embodiment of the invention thus relates to a pre-prepared syringe with a content befitting the average adult or child human being. The average adult or child human weight after which the amount of clotting factor and sympathicomimetic agonist is calculated may be adapted to suit specific circumstances such as children of different age groups (they are expected to increase in weight with age) or different nationalities, as different nations have different mean weights of their inhabitants. The same amount of FVIIa or any clotting factor and adrenaline or noradrenaline or any sympathicomimetic may correspondingly be pressed into a tablet. Likewise, a pre- prepared syringe may be made for the specific purpose of having a duration of 5 min, 10 min, 15 min, 30 min, or 60 min or anything therein between.

Embodiments of use

Clotting factor and sympathicomimetic agonists and/or beta blockers and/or potassium combinations are particularly suitable for the treatment and/or prophylaxis of bleeding, including uncontrolled and excessive bleeding episodes in connection with surgery and other forms of tissue damage. In the following is provided a non-exhaustive description of various conditions were clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium combinations, either administered alone or in combination with any of the above mentioned treatments, are envisaged to be beneficial in controlling or preventing bleedings, due to their above-described systemic hemostatic properties.

Treatment of bleeding caused by trauma

The present invention is useful in any situation wherein an individual is bleeding e.g. trauma, or is expected to bleed eg. during surgery. These two situations differ in several respects: during trauma, if it is at all possible to administer anesthesia, there is no time to wait for the full effect before performing the necessary interventions; during elective surgery, which here is defined as any type of non-acute intervention that will or is expected to cause bleeding, the entire situation is under control from the onset, and there is time to wait for the full effect of the anesthesia to set in. When a patient is fully anesthetized the blood pressure generally lowers. Surprisingly the inventor has found that fully anesthetized patients require less sympathicomimetic agonist for the treatment to be effective: e.g: 3 - 3.5 μg/kg/h for 15 min of adrenaline in combination with a clotting factor is sufficient for the full effect of the treatment, whereas 6 μg/kg/h for 15 min of adrenaline in combination with a clotting factor is required in non- anesthetized patients, please see Figures 14 and 15 showing TEG MA results for awake volunteers (Figure 14) and anesthetized patients undergoing prostatectomy (Figure 15).

In subjects who experience extensive tissue damage in association with surgery or vast trauma, the normal hemostatic mechanism may be overwhelmed by the demand of immediate hemostasis and they may develop bleeding in spite of a normal hemostatic mechanism. It is envisaged that in any form of trauma, systemic administration of clotting factors and sympathicomimetic agonists may be beneficial to the subject. As used herein, the term "trauma" is intended to mean injury to living tissue caused by an extrinsic agent.

Hemorrhage as a result of trauma can start a cascade of problems. For example physiological compensation mechanisms are initiated with the initial peripheral mesenteric vasoconstriction to shunt blood to the central circulation. If circulation is not restored, hypovolaemic shock ensures (multiple organ failure due to inadequate perfusion.) Trauma patients may develop hypothermia due to environmental conditions at the scene, inadequate protection, intravenous fluid and blood product administration and ongoing blood loss. Deficiencies in coagulation factors and platelets can result from blood loss, dilution, consumption or transfusions. Meanwhile acidosis and hypothermia interfere with normal blood clotting mechanisms. Thus coagulophathy develops which may mask surgical bleeding sites and hamper control of mechanical bleeding. Hypothermia, coagulophathy and acidosis are often characterized as the "lethal triad" as these conditions often lead to uncontrollable blood loss, multiple organ failure and death typically in an intensive care unit.

In addition to hypovolaemic shock as a result of blood loss, shock may also develop as a result of activation of the inflammatory pathways, resulting in a hypocoagulant state. This subset of trauma patients has particularly high mortality.

One general aspect of the invention therefore relates to methods of treatment of bleeding in patients suffering from various forms of trauma. The trauma may be any type of trauma such as blunt trauma and penetrating trauma; the invention is particularly well suited for treating bleeding following penetrating trauma.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma in a subject, comprising administering to said subject a clotting factor and a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards the head and/or neck including but not limited to the brain, eye(s), ear(s), nose, mouth, esophagus, trachea, soft tissues, muscles, bones and / or vessel(s) in a subject, comprising administering to said subject a clotting factor a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards the thoracic region including but not limited to the heart, lungs, oesophagus, soft tissues, muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium. In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards the abdomen including but not limited to the liver, pancreas, spleen, ventricle, gall-bladder, intestines, or retroperitoneal tissue, soft tissues, muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards the pelvis including but not limited to prostate, urinary bladder, uterus, ovarii, bones i.e. pelvic ring, hip, femur, soft tissues, muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards the long bones of the extremities including but not limited to humerus, ulnae, radii and/or bones of the hand, femur, tibia, fibula and/or bones of the foot, the columnae, scapulae, costae, clavicle or in any combination hereof in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards any combination of the above in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by trauma towards any combination of the above in a subject, comprising administering to said subject a clotting factor such as FVIIa in a dose of about 20 microgram/kg, a sympathicomimetic agonist such as adrenalin in a dose of about 6 microgram/kg and/or potassium.

In another embodiment, the invention relates to a method for the treatment of subjects suffering from shock as a result of blood loss after trauma comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium. In an additional embodiment, the invention relates to use of clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in connection with any of the indications discussed above.

In yet another embodiment, the invention relates a clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in connection with any of the indications discussed above.

Treatment of bleedings in the brain and central nervous system

Intracerebral hemorrhage (ICH) is the most deadly form of stroke. In addition to high short-term mortality rates, ICH also results in very high rates of severe mental and physical disability among survivors. The causes of ICH are numerous and can include head trauma, traumatic brain injury (TBI), hypertensive hemorrhage, transformation of prior ischemic infarction (ischemic stroke), metastatic brain tumor, coagulophathy, drug induced ICH, arteriovenous malformation, aneurysm, amyloid angiopathy, cavernous angioma, dural arteriosvenous fistula and capillary telaniectasias.

A further embodiment of this aspect of the invention relates to methods for the treatment of primary intracerebral bleeding (ICH) in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to use of clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in connection with any of the ICH-related causes of a subject as discussed above.

In yet another embodiment, the invention relates a clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in connection with any of the ICH-related causes of a subject as discussed above.

Treatments of surgical bleeds

Another situation is when subjects are to undergo elective or acute surgical interventions where bleeding may occur and hence where administration of blood products may become necessary. The surgery may be either a scheduled or acute procedure, and may be any type of surgery on any part of the body.

One embodiment of this aspect of the invention thus relates to methods for the treatment of a subject in connection with surgical inventions, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

Additionally, the invention relates to use of clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for the treatment of bleeding in connection with surgery as discussed above.

One general aspect of the invention therefore relates to methods of treatment of bleeding in patients suffering from / undergoing various forms of surgery.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in the head and/or neck including but not limited to the brain, eye(s), ear(s), nose, mouth, esophagus, trachea, bones, soft tissue, muscles and vessel(s) in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in the thoracic region including but not limited to the heart, lungs, oesophagus, soft tissue, muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in the abdomen including but not limited to the liver, pancreas, spleen, kidney, adrenal glands, ventricle, gall-bladder, intestines, retroperitoneal tissue, soft tissue, muscles or any vessel or vessels in a subject, comprising administering to said subject a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in the pelvis including but not limited to prostate, urinary bladder, uterus, ovarii, bones i.e. pelvic ring, hip, femur, soft tissue, muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery of the long bones of the extremities including but not limited to humerus, ulnae, radii and/or bones of the hand, femur, tibia, fibula and/or bones of the foot, the columnae, scapulae, costae, clavicle, soft tissue, muscles or in any combination hereof in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by surgery in any combination of the above in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

Additionally, the invention relates a clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in connection with surgery as discussed above.

Treatment of bleedings associated with vascular defects

Bleeding secondary to vascular defects may arise due to congenital or acquired defects of the vascular system resulting in aneurysms of arteries and or veins, arterioveinuous malformations or rupture of atherosclerotic plaques. These bleedings may be severe or life-threatening depending on localization i.e. intracerebral and/or the size of vessel(s) affected, exemplified by ruptured aortic lesions. One embodiment of this aspect of the invention thus relates to methods for the treatment of a subject in connection with vascular defects, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

Additionally, the invention relates to use of clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for the treatment of bleeding in connection with vascular defects as discussed above.

One general aspect of the invention therefore relates to methods of treatment of bleeding in patients suffering from various forms of vascular defects.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in the head and/or neck region including, but not limited to the brain, eye(s), ear(s), nose, mouth, esophagus, trachea, soft tissue or muscles in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in the thoracic region including but not limited to the heart, lungs, esophagus, soft tissue or muscles or any other vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in the abdomen including but not limited to the liver, pancreas, spleen, kidney, adrenal glands, ventricle, gall-bladder, intestines, retroperitoneal tissue, soft tissue or muscles or any other vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium. In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in the pelvis including but not limited to prostate, urinary bladder, uterus, ovarii, bones i.e. pelvic ring, hip, femur, soft tissue or muscles or any vessel or vessels in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in the soft tissue and /or muscles surrounding of the long bones of the extremities including but not limited to humerus, ulnae, radii and/or bones of the hand, femur, tibia, fibula and/or bones of the foot, the columnae, scapulae, costae, clavicle, soft tissue or muscles or in any combination hereof in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In one embodiment, the invention thus relates to a method for the treatment of bleeding caused by vascular defects in any combination of the above in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

Additionally, the invention relates to use of clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for the treatment of bleeding in connection with various forms of vascular defects discussed above.

In another embodiment the invention relates a clotting factor, a sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in connection with various forms of vascular defects discussed above.

Treatment of bleeding associated with biopsies and laparoscopic surgery

A further aspect of the invention relates to methods of treatment of bleeding in subject undergoing biopsies from various organs (brain, heart, liver, lung, pancreas, spleen, lymphoid tissue, intestines, adrenal glands, tumors, soft tissue, muscles, gastrointestinal tract) as well as in laparoscopic surgery. In one embodiment, the invention thus relates to a method for the treatment of bleeding in subjects undergoing biopsies, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In another embodiment, the invention relates to a method for the treatment of bleeding in subjects undergoing laparoscopic surgery, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to the use of clotting factors, sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding as a in a subject undergoing biopsies as discussed above or undergoing laparoscopic surgery.

Treatment of bleeding caused by coagulopathy Uncontrolled and/or excessive bleeding may occur in subjects having a normal coagulation system and subjects having coagulation or bleeding disorders. Excessive bleedings may also occur in subjects with a normally functioning blood clotting cascade (no clotting factor deficiencies or -inhibitors against any of the coagulation factors).

Bleeding secondary to coagulopathy i.e. coagulation factor dilution with crystalloids and or colloids and/or blood products and/or consumption such as but not limited to infection, sepsis, DIC (disseminated intravascular coagulation), haematological disorders and malignancies, graft vs. host disease, inhibitors against coagulation factors.

In one embodiment, the invention relates to a method for the treatment of bleeding in a coagulopathic subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to use of clotting factors, and sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in a coagulopathic subject. In yet another embodiment, the invention clotting factors, and sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in a coagulopathic subject.

The invention does not relate to use of clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in a subject with haemophilia.

Treatment of bleeding as a consequence of treatment with anticoagulants/antithrombotics

Bleeding, also acute and/or profuse may also occur in subjects on anticoagulant therapy in whom a defective hemostasis has been induced by the therapy given. Such subjects may need surgical interventions in case the anticoagulant effect has to be counteracted rapidly. Another situation that may cause problems in the case of unsatisfactory hemostasis is when subjects with a normal hemostatic mechanism are given anticoagulant therapy to prevent thromboembolic disease. Such therapy may include heparin both unfractionated and low molecular weight, other forms of proteoglycans, activated protein C, antithrombin, tissue factor pathway inhibitor, warfarin or other forms of vitamin K-antagonists as well as aspirin, dipyrimidol, , NSAID, GPIIb/llla inhibitors, Flolan (prostacyclin) ADP receptor inhibitors, direct thrombin inhibitors, hirudin, citrate, and other platelet activation/aggregation inhibitors. A further general aspect of the invention therefore relates to methods of treatment of bleeding in connection with anticoagulant therapy.

In one embodiment, the invention thus relates to a method for treatment of bleeding in a subject receiving an anticoagulant and antithrombotic drug, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to use of clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding complication due to anticoagulant treatment in a subject. In yet another embodiment, the invention relates to clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding complication due to anticoagulant treatment in a subject.

Treatment of thrombocytopenic subjects

Thrombocytopenic subjects are characterized by a reduced blood platelet (thrombocyte) count resulting from a reduced platelet production and/or an increased loss of platelets. There are numerous causes of thrombocytopenia such as decreased bone marrow production of megakaryocytes (e.g. due to marrow infiltration with tumor or fibrosis, or marrow failure induced by e.g. aplasia, hypoplastic anemias, or chemotherapy or other drugs), splenic sequestration of circulating platelets (e.g. splenic enlargement due to tumor infiltration or plenic congestion due to portal hypertension), increased destruction of circulating platelets (e.g. due to vascular prosthese, cardiac valves, disseminated intravascular coagulation (DIC), sepsis, vasculitis, autoantibodies to platelets, drug-associated antibodies, or circulating immune complexes induced by systemic lupus erythematosis, viral agents, bacterial sepsis or idiopathic thrombocytopenic pupora (ITP), platelet disorders, von Willebrands disease, Bernhard-Soulier syndrome, Glanzmann's thrombasthenia, decreased cyclooxygenase activity (drug induced or congeniital), granule storage pool defects (acquired or congenital), uremia, platelet coating (e.g. due to penicillin or paraproteins), defective platelet coagulant activity (Scott's syndrome, or thrombocytopenia associated with liver disease such as caused by hepatitis C or hepatitis B, or caused by IFN-alpha treatment of hepatitis C or hepatitis B as well as secondary to hypersplenism

Another general aspect of the invention thus relates to treatment of bleeding in connection with thrombocytopenia caused by e.g. any of the conditions discussed above.

In one embodiment, the invention thus relates to a method for treatment of bleeding in connection with thrombocytopenia in a subject, comprising administering to said subject clotting factor, a a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to use of clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in connection with thrombocytopenia caused by e.g. any of the conditions discussed above.

Another aspect of the invention relates to the treatment of bleeding in a subject caused by a combination of coagulopathy (coagulation factor deficiency) and thrombocytopenia (low platelet count) or due to low platelet function

In one embodiment, the invention thus relates to a method for treatment of bleeding in connection with a combination of coagulopathy (acquired or congenital) and thrombocytopenia (acquired or congenital) in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to the use of clotting factors and sympathicomimetic agonists for the preparation of a medicament for treatment of bleeding in connection with coagulopathy (acquired or congenital) and thrombocytopenia (acquired or congenital) caused by e.g. any of the conditions discussed above.

In yet another embodiment, the invention relates to clotting factors and sympathicomimetic agonists use in the treatment of bleeding in connection with coagulopathy (acquired or congenital) and thrombocytopenia (acquired or congenital) caused by e.g. any of the conditions discussed above.

Treatment of bleedings associated with transplantation

Patients undergoing transplantation of solid organs, such as but not limited to liver, heart, lungs, pancreas, kidneys and/or intestines are at high risk of developing bleeding due to the surgically induced bleeding. Also patients undergoing hematopoietic stem cell or bone marrow transplantation are at risk of bleeding due to the conditioning of the patients with body irradiation and chemotherapy eradicating the patients hematopoietic system and hence severely deficient of platelets and red blood cells. In the post- transplant period these patients are at risk of developing graft vs. host disease, which may result in bleedings from the liver, gastrointestinal and urogenital system as well as from the bronchioalveolar system. In one embodiment, the invention thus relates to a method for treatment of bleeding in connection with solid organ or hematopoietic system transplantation in a subject, comprising administering to said subject a clotting factor, a sympathicomimetic agonist and/or a beta blocker and/or potassium.

In an additional embodiment, the invention relates to use of clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for the preparation of a medicament for treatment of bleeding in connection with solid organ or hematopoietic system transplantation caused by e.g. any of the conditions discussed above.

In an additional embodiment, the invention relates to clotting factors and sympathicomimetic agonists and/or beta blockers and/or potassium for use in the treatment of bleeding in connection with solid organ or hematopoietic system transplantation caused by e.g. any of the conditions discussed above.

Items:

In a specific embodiment of the present invention, the clotting factor comprises FVIIa or a variant or analogue thereof and the sympathicomimetic agonists comprise adrenaline and/or noradrenaline and/or dobutamine and the beta blocker is Seloken and/or

Esmolol and/or Landiolol. The adrenaline and/or noradrenaline and/or dobutamine and Seloken and/or Esmolol and/or Landiolol are administered to prevent or treat bleeding in a subject.

In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is adrenaline and is administered in combination with Seloken.

In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is adrenaline and is administered in combination with Landiolol.

In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is adrenaline and is administered in combination with Esmolol. In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is noradrenaline and is administered in combination with Seloken.

In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is noradrenaline and is administered in combination with Landiolol.

In a still further embodiment of the present invention, the clotting factor comprises or is FVIIa, rFVIIa or a variant or analogue thereof and the sympathicomimetic agonist comprises or is noradrenaline and is administered in combination with Esmolol.

Another embodiment of the invention relates to a composition comprising a clotting factor, an adrenergic receptor agonist and a beta blocker for the treatment or prophylaxis of bleeding in a subject.

In a still further embodiment of the present invention, the adrenergic receptor agonist is any of adrenaline, noradrenaline, dobutamine, dopamine, dobutrex and ephedrine.

In a still further embodiment of the present invention, the adrenergic receptor agonist is adrenaline.

In a still further embodiment of the present invention, the adrenergic receptor agonist is noradrenaline.

In a still further embodiment of the present invention, the clotting factor is any of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof, and FII, FV, FVII, FVIII, FIX, FX, FXII and FXII or a variant or analogue thereof.

In a still further embodiment of the present invention, the clotting factor is FVIIa, rFVIIa, rhFVIIa, FVII, rFVII, or a variant or analogue thereof.

In a still further embodiment of the present invention, the beta blocker has a high cardioselectivity. In a still further embodiment of the present invention, the beta blocker is any of Seloken, Esmolol and Landiolol.

In a still further embodiment of the present invention, the beta blocker is Seloken.

In a still further embodiment of the present invention, the beta blocker is Esmolol.

In a still further embodiment of the present invention, the beta blocker is Landiolol.

In a still further embodiment of the present invention, the composition according is for systemic administration.

In a still further embodiment of the present invention, the adrenergic receptor agonist increases a subjects hemostatic ability by altering one or more of the TEG measurable parameters of the blood of a subject to which substance is administered such as: lowering the r value (clotting time), lowering the k value (clot kinetics), increasing the

Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength).

In a still further embodiment of the present invention, the dose of the adrenergic receptor agonist administered is in the range 0.1 to 100 microgram/kg, or 1 microgram/kg to 50 microgram/kg, such as e.g. 2 microgram/kg to 20 microgram/kg, 2.5 microgram/kg to 15 microgram/kg, 3 microgram/kg to 10 microgram/kg or 3.5 microgram/kg 5 microgram/kg.

In a still further embodiment of the present invention, the dose of the adrenergic receptor agonist administered is in the range of 1 to 10 microgram/kg.

In a still further embodiment of the present invention, the dose of the adrenergic receptor agonist is about 2 microgram/kg or more, such as e.g. about 3 microgram/kg or more, or about 4 microgram/kg or more, or about 5 microgram/kg or more, or about 6 microgram/kg or more or about 7 microgram/kg or more.

In a still further embodiment of the present invention, the dose of the clotting factor administered is in the range of 1 to 30 microgram/kg. In a still further embodiment of the present invention, the composition is administered enterally and/or parenterally.

In a still further embodiment of the present invention, the enteral administration is oral, gastric or rectal.

In a still further embodiment of the present invention, the parenteral administration is intravenous, intraarterial, subcutaneous, intramuscular, intrapulmonary via the alveoli, intracardiac, intradermal, transdermal, transmucosal, intrathecal, intraperitoneal, intraosseous and/or intravesical or by other means whereby an appropriate systemic concentration is obtained.

In a still further embodiment of the present invention, the parenteral administration is subcutaneous, intramuscular, intraosseous and/or intravenous.

In a still further embodiment of the present invention, the dose is administered as a single bolus dose or as repeated doses.

In a still further embodiment of the present invention, the dose is administered continuously.

In a still further embodiment of the present invention, the clotting factor, the agonistic substance and the beta blocker are administered simultaneously or separately.

In a still further embodiment of the present invention, the dose of the adrenergic receptor agonist is in the range 0.1 microgram/kg/hour to 25 microgram/kg/hour, such as e.g. 1 microgram/kg/hour to 20 microgram/kg/hour, 2 microgram/kg/hour to 15 microgram/kg/hour, 2.5 microgram/kg/hour to 10 microgram/kg/hour or 3 microgram/kg/hour to 5 microgram/kg/hour.

In a still further embodiment of the present invention, the dose of the adrenergic receptor agonist is about 3 microgram/kg/hour, such as e.g. about 2 microgram/kg/hour or about 4 microgram/kg/hour or about 5 microgram/kg/hour or more, or about 6 microgram/kg/hour or more or about 7 microgram/kg/hour or more. In a still further embodiment of the present invention, the dose of the clotting factor is in the range 0.1 microgram/kg/hour to 30 microgram/kg/hour.

In a still further embodiment of the present invention, the composition if for the treatment or prophylaxis of bleedings associated with vascular defects, biopsies and laparoscopic surgery and transplantation, or in connection with bleedings in the brain or central nervous system, or bleedings caused by trauma, surgery and coagulopathy, or as a consequence of treatment with anticoagulants, or due to congenital or acquired conditions.

Yet another embodiment of the invention relates to a method for the treatment or prophylaxis of bleeding of a subject in need of such a treatment, the method comprises administration of an effective dose of a composition described herein above for the treatment or prophylaxis of bleeding in a subject.

In a still further embodiment of the present invention, the composition described herein above comprises at least one of adrenaline, noradrenaline and dobutamine.

In a still further embodiment of the present invention, the composition comprises at least one of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

Yet another embodiment of the invention relates to a composition for use in a method according described herein, comprising an adrenergic receptor agonist affecting any of the αi, α₂, βi, β₂ receptors of the sympathetic nerve system and a pharmaceutically acceptable excipient.

In a still further embodiment of the present invention the composition is for use in a method described above, comprising any of adrenaline, noradrenaline and dobutamine. In a still further embodiment of the present invention the composition is for use in a method described above, comprising any of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

Yet another embodiment of the invention relates to a kit for use in a method described herein, comprising i) an adrenergic receptor agonist, ii) a clotting factor iii) a beta blocker iv) optionally an aqueous medium to dissolve the adrenergic receptor agonist and/or the clotting factor, and v) instructions for use.

Yet another embodiment of the invention relates to a kit for use in a method described herein, comprising

i)an adrenergic receptor agonist, i) a clotting factor ii) a beta blocker iii) an aqueous medium to dissolve the adrenergic receptor agonist, and iv) optionally, instructions for use.

Yet another embodiment of the invention relates to a kit for use in a method described herein, comprising an adrenergic receptor agonist such adrenaline, noradrenaline and/or dobutamine, a clotting factor such as FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof, and a beta blocker such as Seloken, Esmolol and/or Landiolol.

Yet another embodiment of the invention relates to a composition comprising a clotting factor, an adrenergic receptor agonist, potassium in a pharmaceutically acceptable form and optionally a beta blocker for the treatment or prophylaxis of bleeding in a subject.

In a still further embodiment of the present invention the beta blocker has a high cardioselectivity.

In a still further embodiment of the present invention wherein the beta blocker is any of Seloken, Esmolol and Landiolol.

In a still further embodiment of the present invention the beta blocker is Seloken.

In a still further embodiment of the present invention the beta blocker is Esmolol.

In a still further embodiment of the present invention beta blocker is Landiolol.

Yet another embodiment of the invention relates to a kit for use in a method according to any of claims 99 to 104, comprising an adrenergic receptor agonist such adrenaline, noradrenaline and/or dobutamine, a clotting factor such as FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof, and a beta blocker such as Seloken, Esmolol and/or Landiolol.

Detailed description of the drawings

Figure 1 : TEG technology. See Example 1 for explanation.

Figure 2: TEG parameters. The following parameters are derived from a TEG tracing; R, the time from start of analysis until initial clot formation (at 2 mm amplitude); Angle, representing velocity of clot formation; MA, maximal amplitude, the maximal physical clot strength; Lysis AUC, the area under the fibrinolysis curve calculated from MA (hatched area).

Figure 3: Representative TEG profile of healthy volunteers before and after administration of adrenaline. Whole blood was drawn in 1/10 citrate from an arterial catheter. The citrated whole blood sample rested exactly 30 minutes at room temperature before TEG analysis on the Thrombelastograph Hemostasis Analyser, series 5000 (Haemoscope Corp., Skokie, IL): One ml of citrated whole blood was transferred to a kaolin vial (Haemoscope Corp.) and gently mixed by inversion 5 times. From the kaolin vial 340 μl was added to a plain TEG cup preloaded with 20 μl of 0.2 M CaCI₂ and the analysis started immediately.

Figure 4: TEG parameters (a) R, (b) Angle and (c) MA of 30 healthy volunteers after totally 15 minutes of i.v. administration of adrenaline. The subjects were catheterized and rested 60 minutes before administration of adrenaline was commenced. Adrenaline was step-wise infused intravenously for 5 minutes at each of the doses 3.5 μg/kg/h, 5.0 μg/kg/h and 6.0 μg/kg/h. Blood samples were collected from an arterial catheter at baseline (t=0) and immediately after each dose (t=5, t=10 and t=15). Results are presented as mean with 95% confidence interval (Cl) and analyzed by 1- way ANOVA (Friedman), followed by post hoc Dunn's Multiple Comparison Test, t=0 vs t=5, t=10 and t=15 respectively, ^*p<0.05, ^***p<0.001.

Figure 5: TEG MA measured before and after i.v. infusion of noradrenaline at 4.8 μg/kg/h for 15 minutes in 10 healthy volunteers, mean with 95% Cl. MA before and after noradrenaline was compared by a paired t-test with a p-value <0.05 considered statistically significant.

Figure 6: TEG MA measured before (t=0) and after i.v. infusion of adrenaline at 4.8 μg/kg/h for 15 minutes (t=15) and 30 minutes after discontinuation of adrenaline administration (t=45). Data presented as mean with 95% Cl. Friedman 1-way ANOVA and Bonferroni post hoc test was used for comparing t=0 to t=15 and to t=45, respectively, ^**p<0.01 , ns; non significant.

Figure 7: TEG parameters (a) R, (b) Angle and (c) MA measured as described in figure 3 and example 1 on blood samples collected from patients infused with adrenaline prior to prostatectomy. Ten patients were anesthetized by propofol and haldid and infused with adrenaline i.v. in the doses 1 , 2 and 3 μg/kg/h each for 5 minutes prior to skin incision. Hereafter the patients were prostatectomised according to local protocol. Blood samples were collected from an arterial catheter before adrenaline administration and immediately after each infusion dose (1 , 2 and 3 μg/kg/h) and again 1 hour after discontinuation of adrenaline infusion. Statistics used: One-way ANOVA, Friedman Test, and Dunn's Multiple Comparison post hoc test of "before" compared to each of the following points 1 , 2, 3 μg/kg/h and 1 hour after termination of adrenaline infusion, ^*p<0.05, ^**p<0.01 ,^***p<0.001 , ns: non significant.

Figure 8: Perioperative bleeding (in ml) of the 10 patients described in figure 7 (receiving adrenaline in the step-wise doses 1 , 2 and 3 μg/kg/h) and 10 other prostatectomy patients receiving a 15 minutes continuous adrenaline infusion of 3 μg/kg/h. The 2 intervention groups were compared to 40 controls also undergoing prostatectomy, whereof 20 underwent surgery prior to the interventions and the last 20 after the intervention. All values including median for each group is depicted.

Comparisons between control group and each of the intervention groups was done separately by Mann Whitney test.

Figure 9: Healthy volunteers received adrenaline as described in figure 4. Arterial blood was collected in citrate before and after the last adrenaline dose (t=15) and again 30 minutes after end of infusion (t=45). The blood was analyzed with TEG (described in figure 3) after addition of tissue plasminogen activator (tPA) in a final concentration of 2.4 nM. (a) A representative example of TEG tracings with tPA induced fibrinolysis before and immediately after infusions of adrenaline, (b) Comparisons of the lysis AUC values t=0 vs. t=15 and t=0 vs. t=45, respectively by 1-way ANOVA, Friedman test and post hoc Dunn's Multiple Comparison Test, ^**p<0.01 , ns: not significant.

Figure 10: Seven healthy volunteers received 3 doses of adrenaline infusion lasting for 5 minutes each in the following step-wise increasing doses 3.5, 5.0 and 6.0 μg/kg/h. After resting 1 hour, the subjects received 0.15 μg/kg Seloken i.v. and rested again 30 minutes before repeating the step-wise adrenaline infusions. Blood samples were obtained from an arterial catheter at baseline (t=0.0), after each of the first adrenaline doses (t=5.0, t=10.1 , t=15.0), at baseline after Seloken administration and rest (t=0.1 ) and after each of the subsequent adrenaline infusions (t=5.1 , t=10.1 , t=15.1 ). The blood was analyzed with TEG as described in figure 3 and Example 1. TEG MA values are presented as mean with 95% Cl and analyzed with a 2-way repeated measurements (RM) ANOVA with post hoc Bonferroni adjusted paired t-test of t=0.0 vs. t=5.0, t=10.1 , t=15.0, respectively and t=0.1 vs. t=5.1 , t=10.1 , t=15.1 , ^***p<0.001. Figure 11 : The healthy subjects described in figure 10 were monitored haemodynamically at the same time points as described in figure 10. (a) heart rate (HR), (b) cardiac output (CO), (c) stroke volume (SV), (d) invasive blood pressure: mean arterial pressure, MAP) and (d) total peripheral resistance (TPR). All results are presented as mean with 95% Cl and analyzed with 2-way repeated measurements ANOVA (RM ANOVA) followed by post hoc Bonferroni adjusted paired t-tests comparing baseline to each of the adrenaline concentrations for both treatments (without or with Seloken pre-treatment, respectively). P-values for adrenaline concentration, treatment and cone x treatment effects in the repeated measures model are shown. The cone x treatment is an analysis of the total response/the total pattern, to check whether there is an interaction between concentration and treatment. If the only significant effect was concentration, the post hoc Bonferroni results in respect of significance level are shown (a,c,d). If the effect of cone x treatment was significant (p<0.05), a Friedman 1-way ANOVA was performed for each treatment, followed by a Bonferroni-adjusted paired t-test comparing adrenaline concentrations separately (b). If concentration and treatment effect were significant without a significant cone x treatment effect separate Bonferroni-adjusted paired t-tests were performed directly (e). ^*p<0.05, ^**p<0.01 , ^***p<0.001 , ns: non significant. ANOVA: Analysis of variance.

Figure 12: Three healthy volunteers received 5 doses of adrenaline infusion lasting for 5 minutes each in the following step-wise increasing doses 1 , 3, 5, 7, and 9 μg/kg/h. After resting 1 hour, the subjects received Seloken i.v. 0.20 μg/kg for 10 minutes and rested again 30 minutes before repeating the step-wise adrenaline infusions. Blood samples were obtained from an arterial catheter at baseline (0.0 μg/kg/h)), after each of the first adrenaline doses, at baseline after Seloken administration and rest and after each of the subsequent adrenaline infusions. The blood was analyzed with TEG as described in figure 3 and Example 1. TEG MA values are presented as mean with 95% Cl.

Figure 13: The effect of rFVIIa in a patient with a normal haemostatic competence as evaluated by TEG is depicted herein and demonstrates that the initiation phase of the haemostatic process is accelerated (reduced R) and that the thrombin burst (Angle) is increased, whereas no effect is noticed on the maximal clot strength. Figure 14: TEG MA in awake volunteers. Six healthy volunteers (four males and two females) received intravenous infusion of adrenaline at a dose of 6 microgram/kg/h for 15 minutes. Blood samples for TEG analysis was obtained before start of adrenaline infusion, and 30 min after discontinuation of adrenaline infusion. The blood was analyzed with TEG as described in figure 3 and Example 1. TEG MA values are presented as mean with 95% Cl.

Figure 15: TEG MA in prostatectomy patients during surgery. TEG MA measured as described in figure 3 and example 1 on blood samples collected from patients infused with adrenaline prior to prostatectomy. Ten patients were anesthetized by propofol and haldid and infused with adrenaline i.v. in the doses 1 , 2 and 3 μg/kg/h each for 5 minutes prior to skin incision. Hereafter the patients were prostatectomised according to local protocol. Blood samples were collected from an arterial catheter before adrenaline administration and immediately after each infusion dose (1 , 2 and 3 μg/kg/h) and again 1 hour after discontinuation of adrenaline infusion. Statistics used: One-way ANOVA, Friedman Test, and Dunn's Multiple Comparison post hoc test of "before" compared to each of the following points 1 , 2, 3 μg/kg/h and 1 hour after termination of adrenaline infusion, ^*p<0.05, ^**p<0.01 ,^***p<0.001 , ns: non significant.

Examples

Example 1

Thrombelastography (TEG)

The TEG in vitro assay is suitable for determining important parameters in the hemostatic process including clot strength. The TEG system's approach to monitoring patient hemostasis is based on the premise that the end result of the hemostatic process is the clot. The clot's physical properties determine whether the patient will have normal hemostasis, or will be at increased risk for haemorrhage or thrombosis [Salooja et al. 2001].

The TEG analyzer uses a small whole blood sample in a rotating cup and a pin suspended in the blood by a torsion wire, which is monitored for motion. The torque of the rotating cup is transmitted to the immersed pin only after fibrin and/or fibrin-platelet bonding has linked the cup and pin together (Figure 1 ). The strength and rate of these bonds affect the magnitude of the pin motion such that strong clots move the pin more than less strong clots. Thus, the TEG technology documents the interaction of platelets with the protein coagulation cascade from the time of placing the blood in the analyzer until initial fibrin formation, clot rate strengthening and fibrin-platelet bonding via GPIIb/llla, through eventual clot lysis (Figure 2). The TEG R parameter reflects the initiation phase, reaction time, from start of coagulation until the first fibrin band is formed; the Angle (α) represents the increase in clot strength, clot kinetics, correlating with the thrombin generation. The maximal amplitude (MA) parameter reflects maximal clot strength i.e. the maximal elastic modus of the clot. The area under the lysis curve, i.e. area under curve from MA is obtained (Lysis AUC) reflects degree of fibrinolyis.

The TEG system has been recognized as a uniquely useful tool and has been used extensively in the management of bleeding during major surgical interventions such as liver transplantations [Kang Y. 1995] and cardiovascular procedures [Shore-Lesserson et al. 1999] as well as obstetrics, trauma, neurosurgery, management of deep vein thrombosis, and the monitoring and differentiation among platelet GPIIb/llla antagonists [Di Benedetto 2003]. TEG -guided transfusion therapy aiming at normalizing clot strength (MA) has resulted in a reduction in the use of blood products, a reduction in the rate of re-exploration, prediction of bleeding in cardiac surgery and it is approved by the FDA for the monitoring of patients with heart assist devices. The clinical utility of the TEG rely in its reflection of thrombin generation and the resulting physical properties of the clot [Rivard et al. 2005].

Figure 3 illustrates TEG profiles from a representative volunteer before and after receiving intravenous infusion of adrenaline 3 μg/kg/h for 15 minutes. Adrenaline was mixed with 0.9% NaCI and infused intravenously. A whole blood sample for TEG analysis was drawn into a tube containing citrate (9 volumes of blood into 1 volume of 0.129 M citrate; Vacutainer system, BD Biosciences, Plymouth, UK) and rested for exactly 30 minutes before analysis: Coagulation was initiated by kaolin and re-calcified according to the instructions of the manufacturer: Citrated whole blood was added to a kaolin vial and mixed by gently inversion 5 times before transfer to the TEG cup containing calcium chloride (20 μl of 0.2 M CaCI₂) , which was preloaded into the TEG^® cup as published previously [Johansson et al. 2008]. The hemostatic process was recorded by use of a TEG^® coagulation analyzer (5000 series, Haemoscope Corporation).

As illustrated in Figure 3 and figure 4, the infusion of adrenaline results in a faster initiation of the coagulation process (R shorter), increased amplification and propagation of the coagulation process, i.e. increased thrombin generation (Angle increased) and a clot with an increased mechanical strength (MA increased).

Example 2 We have identified a pro-hemostatic effect of administration of sympathicomimetics, as exemplified by adrenaline infusion in 30 healthy subjects (figure 3 and 4), patients prior to surgery (figure 7), as well as after noradrenaline administration in 10 healthy subjects (figure 5).

We have found a dose dependent increase in the pro-hemostatic effect of administration of sympathicomimetics where a dose of 1 microgram/kg/hour resulted in a smaller change as compared to baseline than 2 microgram/kg/hour did and the pro- hemostatic effect was further improved when 3 microgram/kg/hour was administered (figure 7). A dose-dependent increase in MA response was additionally observed in a series of adrenaline infusion in the doses 3.5, 5.0, 6.0 μg/kg/h (figure 4c).

Example 3

The effect of administration of adrenaline by intravenous infusion on TEG parameters in 10 consecutive patients undergoing prostatectomy.

Patients undergoing prostatectomy were anaesthetized by propofol and haldid. Prior to skin incision the patients received a step-wise i.v. infusion of adrenaline in the doses 1 , 2 and 3 μg/kg/h each for 5 minutes. TEG analyses were performed as described in example 1 , exactly 30 minutes after collection of arterial blood. Blood samples were obtained before and after each dose and 1 hour after discontinuation of adrenaline infusion. As illustrated in figure 7a-c administration of adrenaline result in a significantly faster initiation of the coagulations process (R decreased), increased rate of amplification and increased rate of propagation and thrombin generation (increased Angle) and an increased mechanical strength of the clot (increased MA). Furthermore, the pro-hemostatic effect of adrenaline on clot strength (MA) is abated 60 min after discontinuation of infusion. Importantly, as opposed to other pro-hemostatic therapies such as coagulation factor concentrates, activated coagulation factor concentrates and activated recombinant factor Vila, sympathicomimetics improve clot strength (MA increase) also in humans with a normal hemostatic system, whereas conventional pro- hemostatics only improve the initiation phase (R) and thrombin generation (Angle).

Example 4

The effect of administration of adrenaline by intravenous infusion on perioperative blood loss.

In addition to the enhanced hemostatic response, intravenous administration of adrenaline resulted in a significant reduction in perioperative blood loss. Blood loss of the 10 patients described in example 2 and 10 additional prostatectomy patients receiving a 15 minutes continuous adrenaline infusion of 3 μg/kg/h before skin incision were compared to 40 control patients, not receiving adrenaline, whereof 20 were operated before the interventions and the last 20 subsequently after the intervention (figure 8). Intravenous administration of adrenaline reduced perioperative blood loss significantly.

Example 5

Safety

The pro-hemostatic effect of sympathicomimetics resulting in increased clot strength as evaluated by TEG MA could potentially increase the risk of thrombembolic events in the patients. It has previously been shown that an increase in MA after surgery is associated with increased incidence of thrombembolic complications (McCrath et al. 2005). As can be seen in the figures 6 and 7c and in Example 2, the MA returns to baseline within 30 or 60 minutes, respectively, after discontinuation of adrenaline infusion and, hence, no risk for development of thrombembolic events due to increased clot strength can be anticipated after discontinuation of the drug.

Example 6

Fibrinolysis resistance When challenging the clot in vitro by induction of fibrinolyis, the Lysis AUC obtained by TEG (see figure 2) is a measure of the clot's resistance against fibrinolysis. Healthy subject received step-wise adrenaline infusion as described in figure 4, and blood was collected before (t=0), immediately after the infusion (t=15) and 30 minutes after discontinuation (t=45). Citrated whole blood was analysed precisely 30 minutes after blood collection: The fibrinolysis activator tPA (American Diagnostica) was added in a final concentration of 2.4 nM and TEG was performed as described in Example 1 and figure 3. As shown in figure 9, adrenaline improves the resistance against fibrinolysis by increasing the Lysis AUC significantly (154 %). This effect was abrogated 30 minutes after discontinuation of adrenaline infusion. This clot stabilizing effect described above has not been observed when administering coagulation factors concentrates (activated or non-activated) or recombinant factor Vila.

Example 7 TEG MA in relation to combination of adrenergic receptor agonist and antagonists.

An antagonist directed at the known adrenergic receptors could potentially abrogate the sympathicomimetic induced pro-hemostatic effect as evaluated by TEG MA. Healthy volunteers rested 1 hour before receiving step-wise i.v. administration of adrenaline in the doses 3.5, 5.0 and 6.0 μg/kg/h, five minutes infusion at each dose, as described in figure 4. Hereafter the subjects rested for 1 hour and received an antagonist by i.v. infusion propanolol (primarily a β-2 antagonist, 0.15 mg/kg for 10 minutes), n=8, Urapidil (α-1 antagonist, 50 mg) or Seloken (β-1 antagonist 0.15 mg/kg for 10 minutes), n=7. The subjects rested another 30 minutes after receiving antagonist and the adrenaline administration was repeated as described above. As a control, subjects also received repeated adrenaline administration without antagonist (n=6). Blood samples were collected from an arterial catheter at baseline before adrenaline (0.0) and after each dosing (3.5, 5.0, 6.0) at both adrenaline infusions. Figure 10 illustrates that MA increases after adrenaline administration and that this response was not affected by β-1 blocking (Seloken). None of the other antagonists tested abrogated the MA increase after adrenaline infusion and showed a similar response as depicted for Seloken (figure 10).

Example 8 Hemodynamic effects in relation to administration of a combination of adrenergic receptor agonist and antagonists.

Adrenaline affects the heart and hemodynamic system, primarily through the β-1 receptors. In connection with surgery an increased stress response is seen due to pain, intubation etc. leading to tachycardia and an increased risk of arrhythmias during surgical procedures. Additional anesthetics and/or pain relief and/or β-receptor blocking agents are used to reduce these side effects.

The hemodynamic changes comprising heart rate (HR), cardiac output (CO), stroke volume (SV), mean arterial pressure (MAP) and total peripheral resistance (TPR) were monitored during the protocol described in example 7 and figure 10. Figure 11 depict the hemodynamic changes in response to adrenaline before and after administration of the β-1 receptor antagonist Seloken. Adrenaline alone increased HR significantly, whereas this effect was practically abrogated/normalized when Seloken was infused (Figure 1 1a) and as the effect of treatment nearly showed significance (p<0.052) post hoc separate Bonferroni adjusted paired t-test was completed showing significant differences in HR at the adrenaline doses 5.0 and 6.0 before and after Seloken. The increase in CO in response to adrenaline infusions (figure 11 b) was significantly lower in all adrenaline concentrations when Seloken was administered. The increase in SV

(figure 1 1 c) was not significantly lowered after Seloken administration and no effects on the MAP were detected at any of the adrenaline doses used in the described protocol (figure 1 1d). A significant decrease in TPR was observed for all adrenaline doses both with and without Seloken with a significant effect of Seloken. Separate Bonferroni adjusted t-tests showed a significantly lower decrease in adrenaline response after Seloken treatment (figure 11 e).

In conclusion, infusion of a β-1 receptor blocker almost normalizes the increase in HR, reduces the increase in CO and reduces the decrease in TPR, seen in response to adrenaline infusion.

Example 9

Three healthy volunteers received 5 doses of adrenaline infusion lasting for 5 minutes each in the following step-wise increasing doses 1 , 3, 5, 7, and 9 μg/kg/h. After resting 1 hour, the subjects received Seloken i.v. 0.20 μg/kg for 10 minutes and rested again 30 minutes before repeating the step-wise adrenaline infusions. Blood samples were obtained from an arterial catheter at baseline (0.0 μg/kg/h)), after each of the first adrenaline doses, at baseline after Seloken administration and rest and after each of the subsequent adrenaline infusions. The blood was analyzed with TEG as described in figure 3 and Example 1. TEG MA values are presented as mean with 95% Cl.

Plasma K+ concentrations where followed before and after administration of both adrenaline and Seloken (beta blocker). As can be seen from Table 1 , the plasma potassium concentrations fell following adrenaline administration. The drop in plasma potassium concentration was less when Seloken was administered prior to the administration of adrenaline.

Table 1 : Plasma concentration of K⁺: Plasma potassium (K⁺) was measured in the healthy subjects described in figure 12 before and after adrenaline infusion with 9.0 μg/kg/h before and after Seloken administration.

Example 10

The combined effect of adrenaline and rFVIIa is evaluated by intravenous administration of adrenaline in dose of 6 μg/kg/h for 30 minutes and obtain sequential blood samples from an arterial i.v. line at baseline and every 10 min during the adrenaline infusion. In the laboratory the blood samples will be spiked with rFVIIa and analyzed by TEG. The samples are analyzed by TEG after initiation of coagulation with innovin diluted 1 :42500 after spiking according to the following setup, where tPA is added to a final concentration of 2.4 nM: 1. Whole blood

2. Whole blood + tPA

3. Whole blood + FVIIa (1.25 nM)

4. Whole blood + FVIIa (1.25 nM) + tPA

5. Whole blood + FVIIa (2.5 nM) 6. Whole blood + FVIIa (2.5 nM) + tPA

7. Whole blood + FVIIa (5 nM) 8. Whole blood + FVIIa (5 nM) + tPA

The following TEG parameters are recorded: R, Angle, MA, Ly30 and LyAUC. The following conventional coagulation analyses are obtained on the whole blood samples: APTT, PT, INR, and platelet count.

Example 11

10 healthy volunteers are included in an in vivo cross over study. The healthy volunteers are instrumented, rest for 30 minutes and thereafter a baseline blood sample is obtained.

Hereafter the subjects are randomized to receive one of two treatments a) or b), after which they rest for 3 hours, where after new blood samples are obtained. Then the subjects receive the other treatment (a or b), rest for another 3 hours subsequent to which final blood samples are obtained.

Half of the study subjects receive treatment a) first and then b) and the rest of the subjects receive b) before a).

Treatment a)

Adrenaline at a concentration of 6 ug/kg/h is infused and blood samples are obtained every 10 min for 30 min, after which the infusion is discontinued.

Treatment b) Adrenaline at a concentration of 6 ug/kg/h is infused and rFVIIa at a dose of 1 , 3, 5, 10, 15, or 20 ug/kg is administered as a bolus and blood samples are obtained every 10 min for 30 min, after which the infusion is discontinued.

All blood samples are drawn from an arterial line and analysed by TEG collecting the following parameters R, Angles, MA and LysisAUC.

Example 12

Adrenaline at a dose ranging from 3 to 15 μg/kg is administered as a continuous infusion into patients undergoing surgery and rFVIIa is administered to half of the patients as a single bolus (1 to 20 μg/kg) dose immediately the adrenaline infusion is commenced. Intraoperative blood loss is compared between groups receiving adrenaline only and adrenaline and rFVIIa in combination.

Example 13

Adrenaline at a dose ranging from 3-15 μg/kg/h is administered as a continuous infusion into healthy volunteers or patients and rFVIIa is administered as a single bolus (1-20 μg/kg) dose immediately the adrenaline infusion is commenced. Sequential blood samples are taken every 5 minutes during the first 30 min of adrenaline infusion. In the laboratory the blood samples will be spiked with the rFVIIa in doses ranging from 1-20 μg/kg and evaluated by TEG. The following TEG parameters are recorded: R, Angle, MA, Ly30 (amplitude of the TEG tracing 30 min after maximum amplitude (MA) and LyAUC. The following conventional coagulation analyses are obtained: APTT (activated partial thromboplastin time), PT (prothrombin time), INR (international normalized ratio), and platelet count.

Example 14

Ex vivo spiking with rFVIIa after adrenalin infusion

Six healthy volunteers (four males and two females) received intravenous infusion of adrenaline at a dose of 6 microgram/kg/h for 15 minutes. Blood samples for TEG analysis was obtained before start of adrenaline infusion, and 30 min after discontinuation of adrenaline infusion.

Ex vivo spiking with rFVIIa at a dose equivalent of 1 , 10 and 100 microgram/kg was added to the whole blood sample obtained immediately after discontinuation of adrenaline infusion and TEG analysis was performed

^*p<0.05

Example 15

Six healthy volunteers (three males and three female) received intravenous infusion of adrenaline at a dose of 6 microgram/kg/h for 15 minutes. Blood samples for TEG analysis was obtained before start of adrenaline infusion, 5 min and 30 min after discontinuation of adrenaline infusion.

Ex vivo spiking with rFVIIa at a dose equivalent of 5, 10 and 20 microgram/kg was added to the whole blood sample obtained 5 min after discontinuation of adrenaline infusion and TEG analysis was performed

^*p<0.05

Conclusion:

Ex vivo addition of rFVIIa increases the velocity of clot initiation/formation as evidenced by a dose -dependent decreased R-value and an increase in Angle with no effect on clot strength.

Addition of 5 microgram/kg rFVIIa results in the same pro-haemostatic effect on whole blood as was seen 30 min after discontinuation of adrenaline infusion.

Addition of rFVIIa at a low dose results in faster maximal pro-haemostatic effect enabling improved haemostatic competence as compared to adrenaline alone.

Addition of rFVIIa in doses above 5 microgram/kg results in a dose-dependent increase in velocity in the initiation phase and in thrombin burst that is more pronounced than what can be achieved with adrenaline alone. This increased in thrombin burst result in a clot that is more resistant against fibrinolysis (LyAUC) than what can be achieved by adrenalin alone, whereas maximal clot strength not is affected.

References

Hoffmann M. A cellbased model of coagulation and the role of factor Vila. Blood Rev. 2003 17:1-5.

Gabriel DA, Li X, Monroe DM 3rd, Roberts HR. Recombinant human factor Vila (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost. 2004 2:1816-22.

Toschi V, GaIIo R, Lettino R, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon,L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human artherosclerotic plaques. Circulation. 1997 4; 95:594-9.

Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth. 2002; 49:S15-20.

Dutton RP, Stein DM. The use of factor Vila in haemorrhagic shock and intracerebral bleeding. Injury. 2006; 37:1172-7.

Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ. Recombinant factor Vila in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion. 2006; 46:919-33.

Kenet g, Walden R, Edad, A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor Vila. Lancet 1999; 354:1879.

Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of recombinant factor Vila in patients with massive haemorrhage is ineffective. Vox Sang. 2004; 86:120-4.

Johansson Pl. Off-label use of recombinant factor Vila for treatment of haemorrhage: results from randomised clinical trials. Vox Sang. 2008;95:1-7.

Friederich, P.W., Henny, C. P., Messelink, E.J., Geerdink, M. G., Keller, T., Kurth, K., Bϋller, H. R., Levi, M. Effect of rFVIIa on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003; 361 : 201-205.

Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost. 2006 Apr;32 Suppl 1 :32-8.

Singh M, Singh P, Kaur H. Plasma protein variations in hemophiliacs receiving factor replacement therapy. Indian J Pediatr. 2007 May;74(5):459-62.

Brace LD. Qualitative platelet disorders. Clin Lab Sci. 2007 Winter;20(1 ):48-55.

Vaslev SN, Knudsen NW, Neligan PJ, Sebastian MW. Massive transfusion exceeding 50 units of blood products in trauma patients. J Trauma 2002;53:291-296

Hardy JF, de Moerloose P, Samama CM. The coagulopathy of massive transfusion. Vox Sang 2005 ;89(3):123-7.

Cheung AT, To PL, Chan DM, Ramanujam S, Barbosa MA, Chen PC, Driessen B, Jahr JS, Gunther RA. Comparison of treatment modalities for hemorrhagic shock. Artif Cells Blood Substit lmmobil Biotechnol. 2007;35(2):173-90.

Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, Saha SP, Hessel EA 2nd, Haan CK, Royston BD, Bridges CR, Higgins RS, Despotis G, Brown JR; Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion, Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, Hill SE, Body S. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007 May;83(5 Suppl):S27-86.

Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE,

Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DB, Norfolk DR, Soldan K, Taylor C, Revill J, Williamson LM, Cohen H; SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev. 2006 Oct;20(4):273-82. Banbury MK, Brizzio ME, Rajeswaran J, Lytle BW, Blackstone EH. Transfusion increases the risk of postoperative infection after cardiovascular surgery. J Am Coll Surg. 2006 Jan;202(1 ):131-8.

Jeschke MG, Chinkes DL, Finnerty CC, Przkora R, Pereira CT, Herndon DN. Blood transfusions are associated with increased risk for development of sepsis in severely burned pediatric patients. Crit Care Med. 2007 Feb;35(2):579-83.

Milasiene V, Stratilatovas E, Characiejus D, Kazbariene B, Norkiene V. TGF-beta1 and TNF-alpha after red blood cell transfusion in colorectal cancer patients. Exp Oncol. 2007 Mar;29(1 ):67-70.

Zallen G, Offner PJ, Moore EE et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg. 1999; 178:570-2.

Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999 Feb 1 1 ;340(6):409-17.

Engoren MC, Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ. Effect of blood transfusion on long-term survival after cardiac operation. Ann Thorac Surg. 2002 Oct;74(4):1 180-6.

Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004 Oct;44(10):1453-62.

Reed W, Lee TH, Norris PJ, Utter GH, Busch MP. Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients. Semin Hematol. 2007 Jan;44(1 ):24-31.

Goldstein DS. Adrenaline and the inner world. Johns Hopkins university Press 2006. Cannon WB, Mendenhall WL. Factors influencing the coagulation of blood. IV The hastening of blood coagulation in pain and emotional excitement. Am J Physiol 1914;34:251-261.

Colman RW, Clowes AW, George JN, Hirsh J, Marder VJ (eds). Hemostasis and Thrombosis. Basic principles and clinical practice. Philadelphia, Williams & Wilkins 2001.

Smith JE: Effects of strenuous exercise on hemostasis. Br J Sports Med 2003;37:433- 435.

el-Sayed MS: Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996;22:282-298.

Teppo H, Virkkunen H, Revonta M. Topical adrenaline in the control of intraoperative bleeding in adenoidectomy: a randomised, controlled trial. Clin Otolaryngol. 2006 Aug;31 (4):303-9.

Johansson Pl. The Blood Bank: From Provider to Partner in Treatment of Massively Bleeding Patients. Transfusion 2007;47:176S-181S.

Welsby IJ, Jiao K, Ortel TL, Brudney CS, Roche AM, Bennett-Guerrero E, Gan TJ. The kaolin-activated Thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth. 2006;20:531-5

Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001 Jul;12(5):327-37.

Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995;21 Suppl 4:34 44.

Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999 Feb;88(2):312-9. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost. 2005 Sep;3(9):2039-43.

Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg. 2004 Nov;99(5):1440-4;

Fries D, Haas T, Klingler A, Streif W, Klima G, Martini J, Wagner-Berger H, lnnerhofer P. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-a porcine model. Br J Anaesth. 2006 Oct;97(4):460-7.

Martini WZ. The effects of hypothermia on fibrinogen metabolism and coagulation function in swine. Metabolism. 2007 Feb;56(2):214-21.

Bassus S, Wegert W, Krause M, Escuriola-Ettinghausen C, Siegemund A, Petros S, Scholz T, Scharrer l, Kreuz W, Engelmann L, Kirchmaier CM. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.PIatelets. 2006 Sep;17(6):378-84.

Gottumukkala VN, Sharma SK, Philip J. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women. Anesth Analg. 1999 Dec;89(6):1453-5.

Velik-Salchner C, Haas T, lnnerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia.J Thromb Haemost. 2007 May;5(5):1019-25

Niemi TT, Suojaranta-Ylinen RT, Kukkonen Sl, Kuitunen AH. Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth Analg. 2006 Apr;102(4):998-1006.

Sorensen B, Ingerslev J. Tailoring hemostatic treatment to patient requirements - an update on monitoring hemostatic response using thrombelastography. Haemophilia. 2005 Nov;1 1 Suppl 1 :1-6 Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S. A novel therapeutic approach combining human plasma- derived Factors Vila and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained hemostatic activity in vivo than obtained with Factor Vila alone. Vox Sang. 2003 Nov;85(4):290-9.

McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576-83.

Claims

1. The use of a clotting factor in combination with an adrenergic receptor agonist for systemic administration for the treatment and/or prophylaxis of bleeding in a subject.

2. The use according to claim 1 , wherein the clotting factor is any of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof , and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII or a variant or analogue thereof.

3. The use according to claim 1 , wherein the clotting factor is any of FVIIa, rFVIIa, rhFVIIa, FVII, rFVII or a variant or analogue thereof.

4. The use according to any of the preceding claims wherein the adrenergic receptor agonist is any of adrenaline, noradrenaline, dobutamine, dopamine, dobutrex and ephedrine.

5. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is adrenaline.

6. The use according to according to any of claims 1 to 4, wherein the adrenergic receptor agonist is noradrenaline.

7. The use according to any of the preceding claims wherein the clotting factor increases a subjects hemostatic ability by altering one or more of the TEG measurable parameters of the blood of a subject to which the substance is administered such as; lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength).

8. The use according to any of the preceding claims wherein the agonistic substance increases a subjects hemostatic ability by altering one or more of the TEG measurable parameters of the blood of a subject to which substance is administered such as: lowering the R value (clotting time), lowering the K value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength).

9. The use according to any of the preceding claims, wherein the clotting factor is administered in a dose in the range of 0.1 to 20 microgram/kg.

10. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is administered in a dose in the range of 0.1 to 100 microgram/kg, or 1 microgram/kg to 50 microgram/kg, such as e.g. 2 microgram/kg to 20 microgram/kg, 2.5 microgram/kg to 15 microgram/kg, 3 microgram/kg to 10 microgram/kg or 3.5 microgram/kg 5 microgram/kg.

1 1. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is administered in a dose in the range of 1 to 10 microgram/kg.

12. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is administered in a dose of about 2 microgram/kg or more, such as e.g. about 3 microgram/kg or more, or about 4 microgram/kg or more or about 5 microgram/kg or more, or about 6 microgram/kg or more or about 7 microgram/kg or more.

13. The use according to any of the preceding claims, wherein the clotting factor and the adrenergic receptor agonist is administered enterally and/or parenterally and the clotting factor and the adrenergic receptor agonist are administered simultaneously or separately.

14. The use according to claim 13, wherein the enteral administration is oral, gastric or rectal.

15. The use according to claim 13, wherein the parenteral administration is intravenous, intraarterial, subcutaneous, intramuscular, intrapulmonary via the alveoli, intracardiac, intradermal, transdermal, transmucosal, intrathecal, intraperitoneal, intraosseous and/or intravesical or by other means whereby an appropriate systemic concentration is obtained.

16. The use according to claim 15, wherein the appropriate systemic concentration is about 1 microgram/kg.

17. The use according to claim 13, wherein the parenteral administration is subcutaneous, intramuscular, intraosseous and/or intravenous.

18. The use according to any of the preceding claims, wherein the clotting factor and/or the adrenergic receptor agonist is administered as a single bolus dose or as repeated doses.

19. The use according to any of the preceding claims, wherein the clotting factor and/or the adrenergic receptor agonist is administered continuously.

20. The use according to any of the preceding claims, wherein the clotting factor is administered in a dose in the range 0.1 microgram/kg/hour to 20 microgram/kg/hour,

21. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is administered in a dose in the range 0.1 microgram/kg/hour to 25 microgram/kg/hour, such as e.g. 1 microgram/kg/hour to 20 microgram/kg/hour, 2 microgram/kg/hour to 15 microgram/kg/hour, 2.5 microgram/kg/hour to 10 microgram/kg/hour or 3 microgram/kg/hour to 5 microgram/kg/hour.

22. The use according to any of the preceding claims, wherein the adrenergic receptor agonist is administered in a dose of about 3 microgram/kg/hour, such as e.g. about 2 microgram/kg/hour or about 4 microgram/kg/hour or about 5 microgram/kg/hour or more, or about 6 microgram/kg/hour or more or about 7 microgram/kg/hour or more.

23. The use according to any of the preceding claims, for the treatment or prophylaxis of bleedings associated with vascular defects, biopsies and laparoscopic surgery and transplantation, or in connection with bleedings in the brain or central nervous system, or bleedings caused by trauma, surgery and coagulopathy, or as a consequence of treatment with anticoagulants, or due to congenital or acquired conditions.

24. The use according to any of the preceding claims, wherein the clotting agent and the adrenergic receptor agonist are formulated for infusion, injection or in a tablet for immediate use optionally in combination with a beta blocker.

25. A method for the treatment or prophylaxis of bleeding of a subject in need of such a treatment, the method comprises administration of an effective dose of clotting factor in combination with an effective dose of adrenergic receptor agonist.

26. A method according to claim 25, wherein the clotting factor comprises at least one of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof, and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII or a variant or analogue thereof.

27. A method according to claims 25 to 26, wherein the adrenergic receptor agonist comprises at least one of adrenaline, noradrenaline and dobutamine.

28. A composition for use in a method according to any of claims 25 to 27, comprising a clotting factor and an adrenergic receptor agonist affecting any of the αi, α₂, βi, β₂ receptors of the sympathetic nerve system and a pharmaceutically acceptable excipient.

29. The composition according to claim 28 for use in a method according to any of claims 25 to 27, comprising any of adrenaline, noradrenaline and dobutamine.

30. A kit for use in a method according to any of claims 25 to 27, comprising i) an adrenergic receptor agonist, ii) a clotting factor iii) optionally an aqueous medium to dissolve the adrenergic receptor agonist and the clotting factor, and iv) instructions for use.

31. A kit for use in a method according to any of claims 25 to 27, comprising i) an adrenergic receptor agonist, ii) a clotting factor iii) an aqueous medium to dissolve the adrenergic receptor agonist and/or the clotting factor, and iv) optionally, instructions for use.

32. A kit for use in a method according to any of claims 25 to 27, comprising adrenaline, noradrenaline and/or dobutamine.

33. A kit for use in a method according to any of claims 25 to 27, comprising FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof, and FII, FV, FVII, FVIII, FIX, FX, FXII and FXII or a variant or analogue thereof.

34. A composition comprising a clotting factor, an adrenergic receptor agonist, potassium in a pharmaceutically acceptable form and optionally a beta blocker for the treatment or prophylaxis of bleeding in a subject.

35. The composition according to claim 34, wherein the adrenergic receptor agonist is any of adrenaline, noradrenaline, dobutamine, dopamine, dobutrex and ephedrine.

36. The composition according to any of claims 34 to 35, wherein the adrenergic receptor agonist is adrenaline.

37. The composition according to any of claims 34 to 36, wherein the adrenergic receptor agonist is noradrenaline.

38. The composition according to claim 34 to 37, wherein the clotting factor is any of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

39. The composition according to claim 34 to 38, wherein the clotting factor is any of FVIIa, rFVIIa, rhFVIIa, FVII, rFVII, or a variant or analogue thereof.

40. The composition according to any of claims 34 to 39, comprising potassium in an amount corresponding to between 1 and 30 mmol/l.

41. The composition according to any of claims 34 to 40, for systemic administration.

42. The composition according to any of claims 34 to 41 , wherein the adrenergic receptor agonist increases a subjects hemostatic ability by altering one or more of the TEG measurable parameters of the blood of a subject to which substance is administered such as: lowering the r value (clotting time), lowering the k value (clot kinetics), increasing the Angle or alpha (representing velocity of clot formation), and/or increasing the MA, maximal amplitude, (the maximal physical clot strength).

43. The composition according to any of claims 34 to 42, wherein the dose of the adrenergic receptor agonist administered is in the range 0.1 to 100 microgram/kg, or 1 microgram/kg to 50 microgram/kg, such as e.g. 2 microgram/kg to 20 microgram/kg, 2.5 microgram/kg to 15 microgram/kg, 3 microgram/kg to 10 microgram/kg or 3.5 microgram/kg 5 microgram/kg.

44. The composition according to any of claims 34 to 43, wherein the dose of the adrenergic receptor agonist administered is in the range of 1 to 10 microgram/kg.

45. The composition according to any of claims 34 to 44, wherein the dose of the adrenergic receptor agonist is about 2 microgram/kg or more, such as e.g. about 3 microgram/kg or more, or about 4 microgram/kg or more or about 5 microgram/kg or more, or about 6 microgram/kg or more or about 7 microgram/kg or more.

46. The composition according to any of claims 34 to 45, wherein the dose of the clotting factor administered is in the range 1 to 20 microgram/kg.

47. The composition according to any of claims 34 to 46, wherein the composition is administered enterally and/or parenterally.

48. The administration according to claim 48, wherein the enteral administration is oral, gastric or rectal.

49. The composition according to claim 48, wherein the parenteral administration is intravenous, intraarterial, subcutaneous, intramuscular, intrapulmonary via the alveoli, intracardiac, intradermal, transdermal, transmucosal, intrathecal, intraperitoneal, intraosseous and/or intravesical or by other means whereby an appropriate systemic concentration is obtained.

50. The composition according to claim 49, wherein the parenteral administration is subcutaneous, intramuscular and/or intravenous.

51. The composition according to any of claims 34 to 50, wherein the dose is administered as a single bolus dose or as repeated doses.

52. The composition according to any of claims 34 to 50, wherein the dose is administered continuously.

53. The composition according to any of claims 34 to 52, wherein the clotting factor, the adrenergic receptor agonist and the potassium and optionally the beta blocker are administered simultaneously or separately.

54. The composition according to any of claims 34 to 53, wherein the dose of the adrenergic receptor agonist is in the range 0.1 microgram/kg/hour to 25 microgram/kg/hour, such as e.g. 1 microgram/kg/hour to 20 microgram/kg/hour, 2 microgram/kg/hour to 15 microgram/kg/hour, 2.5 microgram/kg/hour to 10 microgram/kg/hour or 3 microgram/kg/hour to 5 microgram/kg/hour.

55. The composition according to any of claims 34 to 54, wherein the dose of the adrenergic receptor agonist is about 3 microgram/kg/hour, such as e.g. about 2 microgram/kg/hour or about 4 microgram/kg/hour or about 5 microgram/kg/hour or more, or about 6 microgram/kg/hour or more or about 7 microgram/kg/hour or more.

56. The composition according to any of the claims 34 to 55, wherein the dose of the clotting factor is in the range of 0.1 - 20 microgram/kg/hour.

57. The composition according to any of claims 34 to 56, for the treatment or prophylaxis of bleedings associated with vascular defects, biopsies and laparoscopic surgery and transplantation, or in connection with bleedings in the brain or central nervous system, or bleedings caused by trauma, surgery and coagulopathy, or as a consequence of treatment with anticoagulants, or due to congenital or acquired conditions.

58. A method for the treatment or prophylaxis of bleeding of a subject in need of such a treatment, the method comprises administration of an effective dose of a composition according to any of claims 34 to 57 for the treatment or prophylaxis of bleeding in a subject.

59. A method according to claim 58, wherein the composition comprises at least one of adrenaline, noradrenaline and dobutamine.

60. A method according to any of claims 58 to 59, wherein the composition comprises at least one of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

61. A composition for use in a method according to any of claims 58 to 60, comprising an adrenergic receptor agonist affecting any of the αi, α₂, βi, β₂ receptors of the sympathetic nerve system and a pharmaceutically acceptable excipient.

62. The composition for use in a method according to any of claims 58 to 60, comprising any of adrenaline, noradrenaline and dobutamine.

63. The composition for use in a method according to any of claims 58 to 60, comprising any of FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof.

64. A kit for use in a method according to any of claims 58 to 60, comprising vi) an adrenergic receptor agonist, vii) a clotting factor viii) potassium ix) optionally a beta blocker x) optionally an aqueous medium to dissolve the adrenergic receptor agonist, and xi) instructions for use.

65. A kit for use in a method according to any of claims 58 to 60, comprising v) an adrenergic receptor agonist, vi) a clotting factor vii) potassium viii) optionally a beta blocker ix) an aqueous medium to dissolve the adrenergic receptor agonist, and x) optionally, instructions for use.

66. A kit for use in a method according to any of claims 58 to 60, comprising an adrenergic receptor agonist such adrenaline, noradrenaline and/or dobutamine, a clotting factor such as FVIIa, rFVIIa, rhFVIIa, FXIIIa, FIXa, FXa, FIIa, FVa, FVIIIa and FXIIa, or a variant or analogue thereof and the group comprising the unactivated form of the clotting factors and FII, FV, FVII, FVIII, FIX, FX, FXII and FXIII, or a variant or analogue thereof, and optionally a beta blocker such as Seloken, Esmolol and/or Landiolol.